Use: Labeled indications
- Hypercalcemia of malignancy.
- Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE ZOLEDRONIC ACID Injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. (1.1) Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
(1.2) Limitations of Use: The safety and efficacy of zoledronic acid injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia. 1.1 Hypercalcemia of Malignancy Zoledronic Acid Injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cCa) of greater than or equal to 12 mg/dL [3.0 mmol/L] using the formula: cCa in mg/dL = Ca in mg/dL + 0.8 (4.0 g/dL - patient albumin [g/dL]). 1.2 Multiple Myeloma and Bone Metastases of Solid Tumors Zoledronic Acid Injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy.
Limitations of Use The safety and efficacy of zoledronic acid injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non–tumor-related conditions have not been established.
Contraindications
- Hypersensitivity to zoledronic acid
- Reclast 5 mg: CrCl <35 mL/min or acute renal impairment; hypocalcemia
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS Hypersensitivity to any component of zoledronic acid injection (4) Hypersensitivity to Zoledronic Acid or Any Components of Zoledronic Acid Injection Hypersensitivity reactions including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock have been reported [see Adverse Reactions (6.2)].
Dosing: Adult
- Hypercalcemia of malignancy: 4 mg IV over at least 15 minutes; may repeat after at least 7 days
- Multiple myeloma, bone metastases (CrCl >60): 4 mg IV over at least 15 minutes every 3 to 4 weeks, with calcium 500 mg and vitamin D 400 units daily
- Osteoporosis treatment (Reclast 5 mg): 5 mg IV once a year (CrCl ≥35; contraindicated <35)
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Hypercalcemia of malignancy (2.1)
- 4 mg as a single-use intravenous infusion over no less than 15 minutes. 4 mg as retreatment after a minimum of 7 days. Multiple myeloma and bone metastasis from solid tumors. (2.2)
- 4 mg as a single-use intravenous infusion over no less than 15 minutes every 3-4 weeks for patients with creatinine clearance of greater than 60 mL/min. Reduce the dose for patients with renal impairment. Coadminister oral calcium supplements of 500 mg and a multiple vitamin containing 400 international units of vitamin D daily. Administer through a separate vented infusion line and do not allow to come in contact with any calcium or divalent cation-containing solutions. (2.3)
2.1 Hypercalcemia of Malignancy
2.1 Hypercalcemia of Malignancy The maximum recommended dose of zoledronic acid injection in hypercalcemia of malignancy (albumin-corrected serum calcium greater than or equal to 12 mg/dL [3.0 mmol/L]) is 4 mg. The 4-mg dose must be given as a single-dose intravenous infusion over no less than 15 minutes. Patients who receive zoledronic acid injection should have serum creatinine assessed prior to each treatment.
Dose adjustments of zoledronic acid injection are not necessary in treating patients for hypercalcemia of malignancy presenting with mild-to-moderate renal impairment prior to initiation of therapy (serum creatinine less than 400 µmol/L or less than 4.5 mg/dL). Patients should be adequately rehydrated prior to administration of zoledronic acid injection [see Warnings and Precautions (5.2)].
Consideration should be given to the severity of, as well as the symptoms of, tumor-induced hypercalcemia when considering use of zoledronic acid injection. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment.
Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia.
Retreatment with zoledronic acid injection 4 mg may be considered if serum calcium does not return to normal or remain normal after initial treatment. It is recommended that a minimum of 7 days elapse before retreatment, to allow for full response to the initial dose. Renal function must be carefully monitored in all patients receiving zoledronic acid injection and serum creatinine must be assessed prior to retreatment with zoledronic acid injection [see Warnings and Precautions (5.2)].
2.2 Multiple Myeloma and Bone Metastases of Solid Tumors
2.2 Multiple Myeloma and Bone Metastases of Solid Tumors The recommended dose of zoledronic acid injection in patients with multiple myeloma and metastatic bone lesions from solid tumors for patients with creatinine clearance (CrCl) greater than 60 mL/min is 4 mg infused over no less than 15 minutes every 3 to 4 weeks. The optimal duration of therapy is not known.
Upon treatment initiation, the recommended zoledronic acid injection doses for patients with reduced renal function (mild and moderate renal impairment) are listed in Table 1. These doses are calculated to achieve the same area under the curve (AUC) as that achieved in patients with creatinine clearance of 75 mL/min. CrCl is calculated using the Cockcroft-Gault formula [see Warnings and Precautions (5.2)].
Table 1: Reduced Doses for Patients With Baseline CrCl Less Than or Equal to 60 mL/min Baseline Creatinine Clearance (mL/min) Zoledronic acid Injection Recommended Dose (mg)* greater than 60 4 50 – 60 3.5 40 – 49 3.3 30 – 39 3 * Doses calculated assuming target AUC of 0.66(mg•hr/L) (CrCl = 75 mL/min). During treatment, serum creatinine should be measured before each zoledronic acid injection dose and treatment should be withheld for renal deterioration.
In the clinical studies, renal deterioration was defined as follows: For patients with normal baseline creatinine, increase of 0.5 mg/dL For patients with abnormal baseline creatinine, increase of 1.0 mg/dL In the clinical studies, zoledronic acid injection treatment was resumed only when the creatinine returned to within 10% of the baseline value. Zoledronic Acid Injection should be reinitiated at the same dose as that prior to treatment interruption.
Patients should also be administered an oral calcium supplement of 500 mg and a multiple vitamin containing 400 international units of vitamin D daily.
2.3 Preparation of Solution
2.3 Preparation of Solution Zoledronic Acid Injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs. 4 mg/5 mL Single-Dose Vial for Dilution Prior to Intravenous Infusion Zoledronic acid injection 4 mg/5 mL vial for dilution prior to intravenous infusion contains an overfill to allow withdrawal of 5 mL (equivalent to 4 mg zoledronic acid). Zoledronic acid injection (4 mg/5 mL) should immediately be diluted in 100 mL of sterile 0.9% Sodium Chloride, USP, or 5% Dextrose Injection, USP, following proper aseptic technique, and administered to the patient by intravenous infusion.
Do not store undiluted zoledronic acid injection (4 mg/5 mL) in a syringe, to avoid inadvertent injection. To prepare reduced doses for patients with baseline CrCl less than or equal to 60 mL/min, withdraw the specified volume of the zoledronic acid injection (4 mg/5 mL) from the vial for the dose required (see Table 3).
Table 3: Preparation of Reduced Doses – Zoledronic Acid Injection 4 mg/5 mL Single-Dose Vial for Dilution Remove and use Zoledronic acid Injection Volume (mL) Dose (mg) 4.4 3.5 4.1 3.3 3.8 3.0 The withdrawn zoledronic acid injection (4 mg/5 mL) solution must be diluted in 100 mL of sterile 0.9% Sodium Chloride, USP, or 5% Dextrose Injection, USP. If not used immediately after dilution with infusion media, for microbiological integrity, the solution should be refrigerated at 2°C to 8°C (36°F-46°F).
The refrigerated solution should then be equilibrated to room temperature prior to administration. The total time between dilution, storage in the refrigerator, and end of administration must not exceed 24 hours.
2.4 Method of Administration
2.4 Method of Administration Due to the risk of clinically significant deterioration in renal function, which may progress to renal failure, single doses of zoledronic acid injection should not exceed 4 mg and the duration of infusion should be no less than 15 minutes [see Warnings and Precautions (5.3)]. In the trials and in postmarketing experience, renal deterioration, progression to renal failure and dialysis, have occurred in patients, including those treated with the approved dose of 4 mg infused over 15 minutes.
There have been instances of this occurring after the initial zoledronic acid injection dose.
Dosing: Altered kidney function
Zoledronic acid is a bisphosphonate excreted unchanged by the kidneys and can cause kidney failure. For the 4 mg oncology dose (most PH products), the US label reduces the dose by creatinine clearance (CrCl) from 60 mL/min down to 30 and does not recommend treatment in severe impairment; serum creatinine must be checked before every dose and treatment withheld for kidney deterioration. The 5 mg osteoporosis product (Reclast) is contraindicated below CrCl 35.
Kidney function measure: Label uses Cockcroft-Gault CrCl (mL/min): >60, 50–60, 40–49, 30–39; severe impairment <30. Reclast: CrCl <35.
Show full dosing details
- CrCl ≥60 mL/min
- Myeloma or bone metastases, CrCl >60: 4 mg IV over at least 15 minutes every 3 to 4 weeks. Hypercalcemia of malignancy: 4 mg (no adjustment if serum creatinine <4.5 mg/dL). Reclast 5 mg: no adjustment at CrCl ≥35 (labels). Check serum creatinine before each dose.
- CrCl 30–59 mL/min
- Myeloma or bone metastases: CrCl 50–60, 3.5 mg; 40–49, 3.3 mg; 30–39, 3 mg (label Table 1). Withhold for kidney deterioration (creatinine rise of 0.5 mg/dL from normal, or 1 mg/dL from abnormal baseline) until within 10% of baseline. Reclast 5 mg: contraindicated below CrCl 35.
- CrCl 15–29 mL/min
- Myeloma and bone metastases: not recommended in severe renal impairment (trials excluded serum creatinine above 3.0 mg/dL). Hypercalcemia of malignancy: consider only after weighing risks and benefits. Reclast 5 mg (osteoporosis, Paget's): contraindicated at CrCl <35 mL/min.
- CrCl <15 mL/min (not on dialysis)
- Myeloma and bone metastases: not recommended in severe renal impairment (trials excluded serum creatinine above 3.0 mg/dL). Hypercalcemia of malignancy: consider only after weighing risks and benefits. Reclast 5 mg (osteoporosis, Paget's): contraindicated at CrCl <35 mL/min.
- Hemodialysis (intermittent)
- Not recommended in severe renal impairment (label); not studied in dialysis. Specialist decision (e.g., oncology with nephrology input).
- Peritoneal dialysis
- Not recommended in severe renal impairment (label); not studied. Specialist decision.
- CRRT
- Not recommended in acute kidney injury; Reclast is contraindicated with acute renal impairment (label).
- Dialyzable? Not stated in label. Low protein binding (unbound 60% to 77%), but most of the dose not excreted is bound to bone.
- Monitoring Serum creatinine before every dose; calcium, phosphate, magnesium; hydration before infusion (no diuretic before hypovolemia is corrected). Dental examination (osteonecrosis of the jaw). Thigh or groin pain (atypical femur fracture).
Children (kidney dosing)
- eGFR ≥60
- Not approved for children; kidney dosing not applicable.
- eGFR 30–59
- Not approved for children; kidney dosing not applicable.
- eGFR 15–29
- Not approved for children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not approved for children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not approved for children; kidney dosing not applicable.
- Peritoneal dialysis
- Not approved for children; kidney dosing not applicable.
- CRRT
- Not approved for children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
Renal Insufficiency The pharmacokinetic studies conducted in 64 cancer patients represented typical clinical populations with normal to moderately impaired renal function. Compared to patients with normal renal function (N = 37), patients with mild renal impairment (N = 15) showed an average increase in plasma AUC of 15%, whereas patients with moderate renal impairment (N = 11) showed an average increase in plasma AUC of 43%.
Limited pharmacokinetic data are available for zoledronic acid injection in patients with severe renal impairment (creatinine clearance less than 30 mL/min). Based on population PK/PD modeling, the risk of renal deterioration appears to increase with AUC, which is doubled at a creatinine clearance of 10 mL/min. Creatinine clearance is calculated by the Cockcroft-Gault formula: CrCl = [140-age (years)] x weight (kg) {x 0.85 for female patients} [72 x serum creatinine (mg/dL)] Zoledronic Acid Injection systemic clearance in individual patients can be calculated from the population clearance of zoledronic acid injection, CL (L/h)=6.5(CrCl/90) 0.4.
These formulae can be used to predict the zoledronic acid injection AUC in patients, where CL = Dose/AUC 0-∞. The average AUC 0-24 in patients with normal renal function was 0.42 mg•h/L and the calculated AUC 0-∞ for a patient with creatinine clearance of 75 mL/min was 0.66 mg•h/L following a 4-mg dose of zoledronic acid injection.
However, efficacy and safety of adjusted dosing based on these formulae have not been prospectively assessed [see Warnings and Precautions (5.3)].
Dosing: Pediatric
- Approved ages
- Not indicated in children (label).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use Zoledronic Acid Injection is not indicated for use in children. The safety and effectiveness of zoledronic acid was studied in a one-year active-controlled trial of 152 pediatric subjects (74 receiving zoledronic acid). The enrolled population was subjects with severe osteogenesis imperfecta, aged 1-17 years, 55% male, 84% Caucasian, with a mean lumbar spine bone mineral density (BMD) of 0.431 gm/cm 2, which is 2.7 standard deviations below the mean for age-matched controls (BMD Z-score of -2.7).
At one year, increases in BMD were observed in the zoledronic acid treatment group. However, changes in BMD in individual patients with severe osteogenesis imperfecta did not necessarily correlate with the risk for fracture or the incidence or severity of chronic bone pain. The adverse events observed with zoledronic acid injection use in children did not raise any new safety findings beyond those previously seen in adults treated for hypercalcemia of malignancy or bone metastases.
However, adverse reactions seen more commonly in pediatric patients included pyrexia (61%), arthralgia (26%), hypocalcemia (22%) and headache (22%). These reactions, excluding arthralgia, occurred most frequently within 3 days after the first infusion and became less common with repeat dosing. Because of long-term retention in bone, zoledronic acid injection should only be used in children if the potential benefit outweighs the potential risk.
Plasma zoledronic acid concentration data was obtained from 10 patients with severe osteogenesis imperfecta (4 in the age group of 3-8 years and 6 in the age group of 9-17 years) infused with 0.05 mg/kg dose over 30 min. Mean C max and AUC (0-last) was 167 ng/mL and 220 ng•h/mL, respectively. The plasma concentration time profile of zoledronic acid in pediatric patients represent a multi-exponential decline, as observed in adult cancer patients at an approximately equivalent mg/kg dose.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Clinical studies of zoledronic acid injection in hypercalcemia of malignancy included 34 patients who were 65 years of age or older. No significant differences in response rate or adverse reactions were seen in geriatric patients receiving zoledronic acid injection as compared to younger patients. Controlled clinical studies of zoledronic acid injection in the treatment of multiple myeloma and bone metastases of solid tumors in patients over age 65 revealed similar efficacy and safety in older and younger patients.
Because decreased renal function occurs more commonly in the elderly, special care should be taken to monitor renal function.
Administration
2.3 Preparation of Solution Zoledronic Acid Injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs. 4 mg/5 mL Single-Dose Vial for Dilution Prior to Intravenous Infusion Zoledronic acid injection 4 mg/5 mL vial for dilution prior to intravenous infusion contains an overfill to allow withdrawal of 5 mL (equivalent to 4 mg zoledronic acid). Zoledronic acid injection (4 mg/5 mL) should immediately be diluted in 100 mL of sterile 0.9% Sodium Chloride, USP, or 5% Dextrose Injection, USP, following proper aseptic technique, and administered to the patient by intravenous infusion. Do not store undiluted zoledronic acid injection (4 mg/5 mL) in a syringe, to avoid inadvertent injection. To prepare reduced doses for patients with baseline CrCl less than or equal to 60 mL/min, withdraw the specified volume of the zoledronic acid injection (4 mg/5 mL) from the vial for the dose required (see Table 3). Table 3: Preparation of Reduced Doses – Zoledronic Acid Injection 4 mg/5 mL Single-Dose Vial for Dilution Remove and use Zoledronic acid Injection Volume (mL) Dose (mg) 4.4 3.5 4.1 3.3 3.8 3.0 The withdrawn zoledronic acid injection (4 mg/5 mL) solution must be diluted in 100 mL of sterile 0.9% Sodium Chloride, USP, or 5% Dextrose Injection, USP. If not used immediately after dilution with infusion media, for microbiological integrity, the solution should be refrigerated at 2°C to 8°C (36°F-46°F). The refrigerated solution should then be equilibrated to room temperature prior to administration. The total time between dilution, storage in the refrigerator, and end of administration must not exceed 24 hours.
2.4 Method of Administration Due to the risk of clinically significant deterioration in renal function, which may progress to renal failure, single doses of zoledronic acid injection should not exceed 4 mg and the duration of infusion should be no less than 15 minutes [ see Warnings and Precautions (5.3) ]. In the trials and in postmarketing experience, renal deterioration, progression to renal failure and dialysis, have occurred in patients, including those treated with the approved dose of 4 mg infused over 15 minutes. There have been instances of this occurring after the initial zoledronic acid injection dose.
US FDA labelDosage forms
Philippines
- Lyophilized powder for iv infusion: 4 mg
- ) concentrated solution for injection: 800 mcg/mL (4 mg/5 mL
- Lyophilized powder for injection: 4 mg
- Solution for iv infusion: 4 mg/5 mL, 5 mg/100 mL, 40 mcg/mL, 50 mcg/mL
- Concentrate solution for iv infusion: 4 mg/5 mL
- Concentrate for solution for iv infusion: 4 mg/5 mL
- Solution for injection: 4 mg per 5 mL, 4 mg/5 mL, 5 mg/100 mL
- Lyophilized powder for solution for infusion: 4 mg
- ) concentrate solution for iv infusion: 800 mcg/mL (0.8 mg/mL) (4 mg/5 mL
- ) solution for injection: 40 mcg/mL (4 mg/100 mL
and 11 more forms; see the products table.
Registered products in the Philippines
72 products registered with the Food and Drug Administration (FDA) Philippines list Zoledronic acid as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products72
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Accord Zoledronic 4Zoledronic acid | 4 mg/5 mL Concentrate for Intravenous InfusionClear Colorless Cyclic Olefin Copolymer (COC) Vial with Fluorotec Gray Rubber Stopper and Violet Aluminum Flip-off Seal x 5 mL (Box of 1's) | RxVAT-exempt | INTAS PHARMACEUTICALS LIMITEDIndia | Accord Healthcare Limited - Philippine Branch Office | DRP-8251 | Jun 27, 2029 | |
AclastaZoledronic Acid | 5 mg/100 mL Solution for IV InfusionColorless Plastic Vial with rubber and aluminum cap with flip-off component | RxVAT-exempt | Fresenius Kabi Austria GmbHAustria | Importer: Novartis Healthcare Philippines, Inc. | DR-XY33139 | Mar 27, 2027 | |
BomozidZoledronic Acid | 4 mg Lyophilized Powder for IV Infusion for InjectionUSP Type I Clear and Glass Vial (Box of 1's) | RxVAT-exempt | Adley Formulations Pvt. Ltd.India | ASA Life Philippines Limited Inc. | DR-XY43861 | Nov 6, 2029 | |
CeldronZoledronic Acid (as monohydrate) | 4 mg Lyophilized Powder for IV In fusionUSP Type I Clear Glass Vial (Box of 1 's) | RxVAT-exempt | Celon Laboratories Private LimitedIndia | I.E. Medica, Inc | DRP-5038 | Jan 7, 2029 | |
DronateZoledronic Acid (as monohydrate) | 4 mg/5 mL Concentrate Solution for IV InfusionType I clear tubular glass vial with florotech coated grey bromobutyl rubber stopper and blue aluminum flip-off seal x 5mL (Box of 1's) | RxVAT-exempt | USV Private LimitedIndia | I.E. Medica, Inc. | DRP-10586 | Oct 20, 2031 | |
GolendronicZoledronic Acid (as monohydrate) | 800 mcg/mL (4 mg/5 mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Flip-off Cap x 5mL (Box of 1's) | RxVAT-exempt | Aroma İlaç San. Ltd. ŞtiTurkey | GO Healthcare Pharmaceutical DistributionImporter: Medinova Pharmaceutical Inc.Trader: Polifarma İlaç San. Ve Tic. A.S. | DRP-10892-02 | Dec 14, 2026 | |
HendronicZoledronic Acid | 4 mg Lyophilized Powder for Injection (IV Infusion)Borosilicate Clear Glass Vial (Box of 1's) | RxVAT-exempt | JIANGSU-HENGRUI MEDICINE CO., LTD.China | GOODFELLOW PHARMA CORPORATION | DR-XY42014 | May 8, 2028 | |
LedrocidZoledronic acid (as monohydrate) | 4 mg Lyophilized Powder for Solution for Infusion (I.V.)10 mL USP Type I clear tubular glass vial with grey butyl slotted rubber plug and lavender aluminum seal (Box of 1’s) | RxVAT-exempt | Venus Remedies LimitedIndia | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-12849-01 | Oct 14, 2027 | |
LendrozoZoledronic Acid | 4 mg/5 mL Solution for IV Infusion5 mL Flint Tubular USP Type-I Glass Vial Stoppered with 20 mm Grey Bromo Butyl Omniplex plus Coated Rubber Stopper (RFS) and 20 mm Aluminum Flip Off Light Blue Colour Seals (Box of 1’s) | RxVAT-exempt | Shilpa Medicare LimitedIndia | Ambica International Corporation | DRP-11859 | May 11, 2032 | |
LeuzotexZoledronic Acid | 4 mg/5 mL Concentrate for Solution for IV InfusionUSP Type I Glass Vial (Box of 1's; Box of 5's) | RxVAT-exempt | CJSC BiocadRussia | Diafarm Inc.Importer: Ambica International Corporation | DRP-7277-01 | Jul 28, 2027 | |
LunaZolZoledronic Acid (as monohydrate) | 4 mg Lyophilized Powder for IV Infusion10 mL USP Type I Clear Vial with Rubber Stopper and Aluminum Lavender Flip-off-Seal (Box of 1's) | RxVAT-exempt | Venus Remedies Ltd.India | Getmeds Philippines Inc.Importer: 2mg Incorporated | DRP-14667-02 | Nov 21, 2028 | |
MedronicZoledronic Acid (as Monohydrate) | 4 mg per 5 mL Solution for Injection (I.V.)Type I USP Clear Glass Vial with Rubber Stopper and Aluminum Seal x 5 mL (Box of 1's and 10's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Biologic Life Sciences Corp.Importer: Ollen Pharma Trading, Inc. | DRP-15891-02 | Sep 26, 2029 | |
MyzoleZoledronic acid (as monohydrate) | 4 mg/5 mL Concentrate Solution for IV Infusion5 mL USP Type I flint clear glass vial with grey bromobutyl rubber stopper and maroon red aluminium maroon red flip-off seal (Box of 1's) | RxVAT-exempt | Mylan Laboratories Limited (Specialty Formulation Facility)India | Mylan Philippines Inc. | DR-XY47736 | Feb 22, 2027 | |
NoneZoledronic Acid (as monohydrate) | 4 mg/5 mL Concentrate Solution for IV InfusionType I clear tubular glass vial with florotech coated grey bromobutyl rubber stopper and blue aluminum flip-off seal x 5mL (Box of 1's) | RxVAT-exempt | USV Private LimitedDabhel Daman - 396 210 India | I.E. Medica, Inc. | DRP-10587 | Oct 20, 2031 | |
NoneZoledronic acid | 800 mcg/mL (4mg/5mL) Concentrate Solution for Injection for Intravenous InfusionPolypropylene (PP) Plastic Vial with Bromobutyl Rubber Stopper. Aluminum Seal and Blue Plastic Flip-off Cap x 5 mL (net content) Box of 1 in Plastic Tray. | RxVAT-exempt | Fresenius Kabi Austria GmbHAustria | Fresenius Kabi Philippines, Inc. | DR-XY46420 | Oct 3, 2028 | |
OsteometZoledronic Acid (as monohydrate) | 4 mg/5 mL Concentrate Solution for IV Infusion5 mL clear COP plastic vial with white flip-off cap (Box of 1's) | RxVAT-exempt | PharmIdea SIALatvia | UNILAB, Inc.Trader: Logenex Pharm GmbH | DR-XY44140 | Feb 2, 2030 | |
OsteometZoledronic acid (as monohydrate) | 800 mcg/mL (4 mg/5 mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Flip-Off Cap x 5 mL (Box of 1's) | RxVAT-exempt | Aroma Ilac San. Ltd. StiTurkey | UNILAB, INC.Importer: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac San. Ve Tic. A.S. | DRP-10892-09 | Dec 14, 2026 | |
OsteostrongZoledronic Acid (as monohydrate) | 4 mg Lyophilized Powder for IV InfusionUSP Type I Flint Glass Tubular Vial x 5 mL w/ Pink Polypropylene Flip-off (Box of 1’s) | RxVAT-exempt | Getwell Pharma India Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-5129-08 | Feb 20, 2029 | |
OsteozolZoledronic acid (as monohydrate) | 800 mcg/ mL (4 mg/ 5 mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Flip-Off Cap x 5 mL (Box of 1's) | RxVAT-exempt | Aroma İlaç San. Ltd. ŞtiTurkey | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc.Trader: Polifarma İlaç San. Ve Tic. | DRP-10892-06 | Dec 14, 2026 | |
OstiozoleZoledronic Acid (as monohydrate) | 4 mg Lyophilized Powder for IV InfusionUSP Type I Flint Glass Tubular Vial x 5 mL w/ Pink Polypropylene Flip-off (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Detoxicare Philippines, Inc.Importer: Ambica International Corporation | DRP-5129-03 | Feb 20, 2029 | |
PagnelZoledronic acid (as monohydrate) | 4 mg Lyophilized Powder for Solution for Infusion (I.V.)10 mL USP Type I clear tubular glass vial with Grey butyl slotted rubber plug and lavender aluminum seal (Box of 1's ) | RxVAT-exempt | Venus Remedies LimitedIndia | Despina Pharma Inc. | DRP-12849 | Oct 14, 2027 | |
SaphdronicZoledronic Acid (as monohydrate) | 4mg Lyophilized Powder for IV Infusion10 mL-capacity USP Type I Clear Glass Vial with. Grey Bromobutyl Rubber Plug and Aluminum Flip-off Seal [Box of 1's] | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13195 | Jan 6, 2028 | |
SinresorZoledronic Acid (as monohydrate) | 4 mg Lyophilized Powder For Iv InfusionUSP Type I Colorless Glass Vial with Bromobutyl Rubber and Red Flip-off Aluminium Seal (Box of 1's) | RxVAT-exempt | Laboratorio Kemex S.A.Argentina | Apolloplus Capital Inc.Trader: Bioprofarma Bagó S.A | DR-XY48817 | Jul 18, 2028 | |
SorlivZoledronic acid (as monohydrate) | 4mg/5mL Solution for Intravenous Infusion5 mL flint tubular USP Type I glass vial stoppered with 20 mm grey bromo butyl omniflex plus coated rubber stopper (RFS) and 20 mm aluminum flip off light blue seal (Box of 1's) | RxVAT-exempt | Shilpa Medicare Limited, Unit. 4, Pharmaceutical Formulations SEZIndia | Ambica International Corporation | DRP-13593 | Mar 14, 2028 | |
UnozoidZoledronic Acid | 5 mg/100 mL Solution for IV InfusionLDPE Bottle x 100 mL (Box of 1's) | RxVAT-exempt | Akums Drugs & Pharmaceuticals Ltd. (Plant III-Injectables)India | Medinova Pharmaceutical Inc.Trader: Unosource Pharma Ltd. | DRP-8445 | Oct 14, 2029 | |
Vexonib 4Zoledronic Acid | 4 mg Lyophilized Powder for Injection (IV Infusion)USP Type I Clear glass vial with yellow flip-off cap x 10 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | VE PHARMA INC.Trader: Vexxa Lifesciences Pvt. Ltd. | DR-XY42735 | Oct 3, 2028 | |
XolnicZoledronic acid (as monohydrate) | 4 mg Lyophilized Powder for IV InfusionUSP Type I Flint Tubular Glass Vial (Box of 1's) | RxVAT-exempt | Khandelwal Laboratories Pvt. Ltd.India | Medethix, Inc. | DRP-4944 | Nov 21, 2028 | |
ZdonateZoledronic Acid | 5 mg/100 mL Solution for Injection (IV Infusion)100mL USP Type I Clear Glass Vial with Grey Bromobutyl Rubber Stopper and Golden Red Aluminum Flip-Off Seal (Box of 1's) | RxVAT-exempt | Gland Pharma LimitedIndia | Biocare Lifesciences, Inc. | DRP-9660 | Apr 27, 2031 | |
ZenroniqZoledronic Acid (as monohydrate) | 800 mcg / mL (4 mg / 5 mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Flip-Off Cap x 5 mL (Box of 1's) | RxVAT-exempt | Aroma Ilac San. Ltd. StiTurkey | Amediqo Phils., Inc.Importer: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac, San. Ve Tic. A.S. | DRP-10892-04 | Dec 14, 2026 | |
ZinvelZoledronic acid | 4 mg/5 mL Concentrate Solution for IV InfusionClear Plastic Vial x 5 mL with Aluminum Seal and Magenta (Color code: PK-19) Flip-Off Button in a Box (Box of 1's) | RxVAT-exempt | Gland Pharma LimitedIndia | Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc.Trader: Mega Lifesciences (Australia) Pty. Ltd. | DR-XY44082 | Jan 28, 2030 | |
ZoboneZoledronic Acid | 4 mg/5 mL Concentrate Solution for Infusion (IV)Clear Neutral USP Type I Glass Vial x 5 mL with Grey Rubber Stopper and Baby Blue Flip Top Aluminum Seal (Box of 1’s) | RxVAT-exempt | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc. | DRP-8743 | Aug 13, 2028 | |
Zobone 5Zoledronic Acid | 5 mg/100 mL Solution for Injection (I.V. Infusion)100 mL Type I Colorless Molded Infusion Vial with Grey Rubber Stopper and Flip-off Golden Red Aluminum Seal | RxVAT-exempt | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc. | DRP-9446 | Aug 13, 2028 | |
ZolchoiceZoledronic Acid (as Monohydrate) | 4 mg Lyophilized Powder for IV InfusionUSP Type I Flint Glass Tubular Vial x 5 mL w/ Pink Polypropylene Flip-off (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Pharma 518, Inc.Importer: Ambica International Corporation | DRP-5129-05 | Feb 20, 2029 | |
ZoldrocidZoledronic Acid (as Monohydrate) | 4 mg Lyophilized Powder for IV InfusionUSP Type I Flint Glass Tubular Vial x 5 mL with Pink Polypropylene Flip-off (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Multi Product Line Pharma, Inc.Importer: Ambica International Corporation | DRP-5129-06 | Feb 20, 2029 | |
ZoldromedZoledronic Acid (as monohydrate) | 4 mg Lyophilized Powder for IV InfusionUSP Type I Flint Glass Tubular Vial x 5 mL w/ Pink Polypropylene Flip-off (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Globo Asiatico Enterprises, Inc.Importer: Ambica International Corporation | DRP-5129-04 | Feb 20, 2029 | |
Zoldron-4Zoledronic Acid (as monohydrate) | 4 mg Lyophilized Powder for IV InfusionUSP Type I Flint Glass Tubular Vial x 5 mL w/ Pink Polypropylene Flip-off (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Macropharma CorporationImporter: Ambica International Corporation | DRP-5129 | Feb 20, 2029 | |
ZolechemZoledronic Acid | 4 mg/5 mL Concentrate for Solution for IV InfusionUSP Type I Glass Vial (Box of 1's and 5's) | RxVAT-exempt | CJSC BiocadRussia | Genace Pharma DistributorImporter: Ambica International Corporation | DRP-7277-02 | Jul 28, 2027 | |
ZolechemZoledronic Acid (As Monohydrate) | 800 mcg/mL (4 mg/5 mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Flip-off Cap x 5 mL (Box of 1's) | RxVAT-exempt | Aroma Ilac San. Ltd. STITurkey | Genace Pharma DistributorImporter: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac, San. Ve Tic. A.S. | DRP-10892-05 | Dec 14, 2026 | |
ZolecidZoledronic Acid | 4 mg/5 mL Concentrated Solution for Injection5 mL with grey SP Type I clear glass vial x chlorobutyl rubber stopper, aluminum seal and white flip-off cap (Box of 5's) | RxVAT-exempt | Ratnaris Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-17558 | Feb 13, 2031 | |
ZoledZoledronic Acid (as monohydrate) | 4 mg Lyophilized Powder for IV InfusionUSP Type I Flint Glass Tubular Vial x 5 mL w/ Pink Polypropylene Flip-off (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Genzen Pharmaceutical TradingImporter: Ambica International Corporation | DRP-5129-01 | Feb 20, 2029 | |
Zoledius-4Zoledronic Acid (as zoledronic anhydrous) | 4 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial x 5 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | IUS Bio Pharmaceutical Care Enterprises Inc.Importer: Pharmastar Int'l Trading Corp. | DRP-5046-06 | Aug 13, 2027 | |
ZoledraZoledronic Acid | 4mg/5mL Solution for IV Infusion5mL Clear Plastic Vial with gray bromobutyl rubber stopper, aluminum cap with flip-off component (Box of 1's) | RxVAT-exempt | Gland Pharma Ltd.India | Endure Medical, Inc. | DR-XY43557 | Jul 25, 2029 | |
ZoledsaphZoledronic Acid (as Monohydrate) | 4 mg per 5 mL Concentrated Solution for Intravenous InfusionType I USP Clear Glass Vial with Rubber Stopper and Aluminum Seal x 5 mL (Box of 1's and 10's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Ollen Pharma Trading Inc. | DRP-15891 | Sep 26, 2029 | |
ZoledsaphZoledronic Acid | 50 mcg/mL (5 mg/100 mL) Solution for IV InfusionColorless Plastic Vial x 100 mL (Box of 1's and 10's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Ollen Pharma Trading Inc. | DRP-17721 | May 6, 2031 | |
ZolefonZoledronic acid (as monohydrate) | 4 mg/5 mL Concentrate Solution for IV Infusion5 mL USP Class VI round clear plastic type cyclic olefin polymer (COP) vial with chlorobutyl rubber stopper and red flip-off cap (Box of 1's) | RxVAT-exempt | Pt. Fonko International PharmaceuticalsIndonesia | Glorious Dexa Mandaya, Inc. | DRP-11315 | Feb 28, 2027 | |
Zolemi-4Zoledronic Acid (as zoledronic anhydrous) | 4 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial x 5 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Eminent Healthcare Inc.Importer: Pharmastar Int'l Trading Corp. | DRP-5046-05 | Aug 13, 2027 | |
ZolentraZoledronic acid (as monohydrate) | 800 mcg/mL (4 mg/5 mL) Concentrated Solution for Injection (I.V. Infusion)Type I Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Flip-Off Cap x 5 mL (Box of 1's) | RxVAT-exempt | Aroma Ilac San. Ltd. StiTurkey | Central West Medicale Inc.Importer: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac San. Ve Tic. A.S. | DRP-10892-07 | Dec 14, 2031 | |
ZolerateZoledronic Acid | 4 mg/5 mL Concentrate for Solution for IV InfusionUSP Type I Glass Vial (Box of 1's; Box of 5's) | RxVAT-exempt | CJSC BiocadRussia | Detoxicare Philippines, Inc.Importer: Ambica International Corporation | DRP-7277-03 | Jul 28, 2027 | |
ZolerixZoledronic Acid | 4 mg/5 mL Concentrate for Solution for IV InfusionUSP Type-I Glass Vial (Box of 1's and 5's) | RxVAT-exempt | CJSC BiocadRussia | Ambica International Corporation | DRP-7277 | Jul 28, 2027 | |
Zoleron-4Zoledronic Acid (as Zoledronic Anhydrous) | 4 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial x 5mL (Box of 1's) | RxVAT-exempt | ADMAC LifesciencesIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-5046-01 | Aug 13, 2027 | |
ZolesarZoledronic Acid | 40 mcg/mL Solution for IV InfusionType II glass vial with bromobutyl rubber stopper and aluminium polypropylene flip-off seal x 100 mL (Box of 1's) | RxVAT-exempt | Sichuan Huiyu Pharmaceutical Company LimitedChina | Oncolife Corporation | DR-XY47017 | Oct 31, 2030 | |
ZolesarZoledronic Acid | 50 mcg/mL Solution for IV InfusionType II glass vial with bromobutyl rubber stopper and aluminum polypropylene flip-off seal x 100 mL (Box of 1's) | RxVAT-exempt | Sichuan Huiyu Pharmaceutical Company LimitedChina | Oncolife Corporation | DR-XY47015 | Oct 31, 2030 | |
ZoletalisZoledronic Acid | 4 mg/5 mL Solution for Injection (I.V. Infusion)USP Type I Clear Glass Vial with Grey Stopper and Aluminum Seal (Box of 1's) | RxVAT-exempt | Vitalis S.A.C.I. - Plant 8Colombia | Pan-Ject Pharmaceuticals Corp.Trader: Vitalis S.A.C.I. | DRP-10265 | Jan 14, 2030 | |
Zoletero 4Zoledronic Acid | 4 mg/5 mL Solution for Infusion (IV)Clear Round COP Vial with grey bromobutyl rubber stopper, aluminum seal and pink flip-off cap x 5 mL Box of 1's | RxVAT-exempt | Hetero Labs LimitedIndia | Camber Pharmaceuticals, Inc. | DRP-7429 | Oct 25, 2027 | |
ZolevZoledronic Acid (As Monohydrate) | 800 mcg/mL (4 mg/5 mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Flip-off Cap x 5 mL (Box of 1's) | RxVAT-exempt | Aroma Ilac San. Ltd. StiTurkey | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac, San. Ve Tic. A.S. | DRP-10892-01 | Dec 14, 2026 | |
ZolHealth 4Zoledronic Acid (as zoledronic anhydrous) | 4 mg Lyophilized powder for Injection (IV)USP Type I Glass Vial x 5 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Healthwinds Medical Trading Corp.Importer: Pharmastar Int'l Trading Corp. | DRP-5046-04 | Aug 13, 2027 | |
ZolinicZoledronic Acid (as monohydrate) | 40mcg/mL (4mg/100mL) Solution for Injection (IV Infusion) | RxVAT-exempt | Maxitech Pharma (Pvt) Ltd.Pakistan | Accesspoint International Trading Inc. | DRP-17694 | Feb 18, 2031 | |
ZolmitzZoledronic acid (as monohydrate) | 800 mcg/mL (4mg/5mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Flip-Off Cap x 5 mL (Box of 1's) | RxVAT-exempt | Aroma Ilac San. Ltd. StiTurkey | Genzen Pharmaceutical TradingImporter: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac San Ve Tic A.S. | DRP-10892-08 | Dec 14, 2026 | |
Zolnish-4Zoledronic Acid (as zoledronic anhydrous) | 4 mg Lyophilized Powder for Injection (IV)USP Type I Glass Vial x 5 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | Pharmastar Int'l Trading Corp. | DRP-5046 | Aug 13, 2027 | |
ZologetZoledronic Acid (as zoledronic anhydrous) | 4 mg Lyophilized Powder for Injection (I.V.)USP Type I Glass Vial x 5 mL (Box of 1's) | RxVAT-exempt | Admac LifesciencesIndia | 2MG IncorporatedImporter: Pharmastar Int'l Trading Corp. | DRP-5046-03 | Aug 13, 2027 | |
ZologetZoledronic Acid (as monohydrate) | 4 mg Lyophilized Powder for IV Infusion10 mL USP Type I Clear Glass Vial with Rubber Stopper and Aluminum Lavender Flip-off Seal (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | 2MG Incorporated | DRP-14667 | Nov 21, 2028 | |
ZologetZoledronic Acid (as monohydrate) | 4 mg Lyophilized Powder for IV InfusionUSP Type I Flint Glass Tubular Vial x 5 mL w/ Pink Polypropylene Flip-off Box of 1's | RxVAT-exempt | Getwell PharmaceuticalsIndia | 2MG IncorporatedImporter: Ambica International Corporation | DRP-5129-07 | Feb 20, 2029 | |
ZolomorZoledronic Acid (as monohydrate) | 4 mg Lyophilized Powder for Injection (IV Infusion)10mL-Capacity Type I Clear Glass Vial Sealed with Bromobutyl Rubber Stopper, Aluminum Seal and Flip- Off Cap x 1's + 5mL Sterile Water for Injection in Transparent Plastic Ampoule (Box of of 1's) | RxVAT-exempt | Mason PharmaIndia | Finstad Inc. | DRP-17060 | Sep 17, 2030 | |
ZolorenZoledronic Acid (as monohydrate) | 4 mg Lyophilized Powder for IV Infusion10 mL USP Type 1 Clear Glass Vial with Rubber Stopper and Aluminum Lavender Flip-off Seal (Box of 1's) | RxVAT-exempt | Venus Remedies LimitedIndia | LLE Medical Healthcare DistributorsImporter: 2MG Incorporated | DRP-14667-01 | Nov 21, 2028 | |
ZolphonateZoledronic Acid (as monohydrate) | 4 mg Lyophilized Powder for IV InfusionUSP Type I Flint Glass Tubular Vial x 5 mL w/ Pink Polypropylene Flip-off (Box of 1's) | RxVAT-exempt | Getwell PharmaceuticalsIndia | Ellebasy Medicale TradingImporter: Ambica International Corporation | DRP-5129-02 | Feb 20, 2029 | |
ZolteoZoledronic Acid (as Monohydrate) | 4 mg per 5 mL Solution for Injection (I.V.)Type I USP Clear Glass Vial with Rubber Stopper and Aluminum Seal x 5 mL (Box of 1's) | RxVAT-exempt | Bruck Pharma Private LimitedIndia | Ambitech Biopharmaceuticals, Inc.Importer: Ollen Pharma Trading, Inc. | DRP-15891-01 | Sep 26, 2029 | |
ZolvarZoledronic Acid (as monohydrate) | 4 mg/5 mL Solution for IV Injection (IV Infusion)Type I Borosilicate Glass Ampule; 1 Ampule Packed in Alu/PVC Blister (Box of 48's) | RxVAT-exempt | Varian Pharmed Co.Iran | Medinova Pharmaceutical Inc.Trader: Estimulo Compañero (LLP) | DRP-15648 | Aug 14, 2029 | |
ZometaZoledronic Acid | 4 mg/5 mL Concentrate for Solution for IV InfusionColorless plastic vial x 5 mL with grey rubber stopper and aluminum cap with flip-off component (Box of 1's) | RxVAT-exempt | Fisiopharma S.R.LItaly | Importer: Metro Drug Inc. | DR-XY30242 | Apr 29, 2030 | |
ZometanicZoledronic Acid (as monohydrate) | 4mg / 5mL Concentrate Solution for Intravenous InfusionUSP Type I Clear Colorless Glass Vial with bromobutyl rubber stopper and red coloured flip-off aluminum cap x 5 mL (Box of 1's and 5's) | RxVAT-exempt | Mefar İlaç Sanayii A.Ş.Turkey | Ambica International CorporationTrader: Pharmada İlaç San. Ve Tic. A.Ş. | DRP-13401 | Feb 14, 2028 | |
ZondraxZoledronic Acid (As Monohydrate) | 800 mcg/mL (4 mg/5 mL) Concentrated Solution for Injection (IV Infusion)Type I Colorless Glass Vial with Gray Bromobutyl Rubber Stopper and Flip-off Cap x 5 mL (Box of 1's) | RxVAT-exempt | Aroma Ilac San. Ltd. StiTurkey | The Cathay Drug Co., Inc.Importer: Medinova Pharmaceutical Inc.Trader: Polifarma Ilac, San. Ve Tic. A.S. | DRP-10892-03 | Dec 14, 2026 | |
ZoruxaZoledronic acid | 5mg/100mL Solution for IV InfusionUSP Type I clear glass vial with grey bromobutyl rubber stopper and red aluminum flip-off seal x 100mL Box of 1's | RxVAT-exempt | Gland Pharma LimitedIndia | Metro Drug, Inc.Importer: Mega Lifesciences Limited Inc.Trader: Mega Lifesciences (Australia) Pty. Ltd. | DR-XY46657 | Aug 5, 2029 | |
(no brand name)Zoledronic Acid (as monohydrate) | 800 mcg/mL (0.8 mg/mL) (4mg/5mL) Concentrate Solution For Iv InfusionType I Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with Brown Flip-Off Cap x 5 mL (Box of 1's) | RxVAT-exempt | Therdose Pharma Private LimitedIndia | Medethix, Inc. | DRP-18558 | Jul 30, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Injection: 4 mg/5 mL (0.8 mg/mL) single-dose vial for dilution prior to intravenous infusion. Injection: 4 mg/5 mL (0.8 mg/mL) single-dose vial for dilution prior to intravenous infusion (3)
Warnings/Precautions
- Patients being treated with zoledronic acid injection should not be treated with Reclast ®. (5.1)
- Adequately rehydrate patients with hypercalcemia of malignancy prior to administration of zoledronic acid injection and monitor electrolytes during treatment. (5.2)
- Renal toxicity may be greater in patients with renal impairment. Do not use doses greater than 4 mg. Treatment in patients with severe renal impairment is not recommended. Monitor serum creatinine before each dose. (5.3)
- Osteonecrosis of the jaw (ONJ) has been reported. Preventive dental exams should be performed before starting zoledronic acid injection. Avoid invasive dental procedures. (5.4)
- Severe incapacitating bone, joint, and/or muscle pain may occur. Discontinue zoledronic acid injection if severe symptoms occur. (5.5)
- Atypical subtrochanteric and diaphyseal femoral fractures have been reported in patients receiving bisphosphonate therapy. These fractures may occur after minimal or no trauma. Evaluate patients with thigh or groin pain to rule out a femoral fracture. Consider drug discontinuation in patients suspected to have an atypical femur fracture. (5.6)
- Hypocalcemia: Correct before initiating zoledronic acid injection. Adequately supplement patients with calcium and vitamin D. Monitor serum calcium closely with concomitant administration of other drugs known to cause hypocalcemia to avoid …
5.1 Drugs With Same Active Ingredient or in the Same Drug Class
5.1 Drugs With Same Active Ingredient or in the Same Drug Class Zoledronic Acid Injection contains the same active ingredient as found in Reclast ® (zoledronic acid). Patients being treated with zoledronic acid injection should not be treated with Reclast or other bisphosphonates.
5.2 Hydration and Electrolyte Monitoring
5.2 Hydration and Electrolyte Monitoring Patients with hypercalcemia of malignancy must be adequately rehydrated prior to administration of zoledronic acid injection. Loop diuretics should not be used until the patient is adequately rehydrated and should be used with caution in combination with zoledronic acid injection in order to avoid hypocalcemia.
Zoledronic Acid Injection should be used with caution with other nephrotoxic drugs. Standard hypercalcemia-related metabolic parameters, such as serum levels of calcium, phosphate, and magnesium, as well as serum creatinine, should be carefully monitored following initiation of therapy with zoledronic acid injection. If hypocalcemia, hypophosphatemia, or hypomagnesemia occur, short-term supplemental therapy may be necessary.
5.3 Renal Impairment
5.3 Renal Impairment Zoledronic Acid Injection is excreted intact primarily via the kidney, and the risk of adverse reactions, in particular renal adverse reactions, may be greater in patients with impaired renal function. Safety and pharmacokinetic data are limited in patients with severe renal impairment and the risk of renal deterioration is increased [see Adverse Reactions (6.1)].
Preexisting renal insufficiency and multiple cycles of zoledronic acid injection and other bisphosphonates are risk factors for subsequent renal deterioration with zoledronic acid injection. Factors predisposing to renal deterioration, such as dehydration or the use of other nephrotoxic drugs, should be identified and managed, if possible.
Zoledronic Acid Injection treatment in patients with hypercalcemia of malignancy with severe renal impairment should be considered only after evaluating the risks and benefits of treatment [see Dosage and Administration (2.1)]. In the clinical studies, patients with serum creatinine greater than 400 µmol/L or greater than 4.5 mg/dL were excluded.
Zoledronic Acid Injection treatment is not recommended in patients with bone metastases with severe renal impairment. In the clinical studies, patients with serum creatinine greater than 265 µmol/L or greater than 3.0 mg/dL were excluded and there were only 8 of 564 patients treated with zoledronic acid injection 4 mg by 15-minute infusion with a baseline creatinine greater than 2 mg/dL.
Limited pharmacokinetic data exists in patients with creatinine clearance less than 30 mL/min [see Clinical Pharmacology (12.3)].
5.4 Osteonecrosis of the Jaw
5.4 Osteonecrosis of the Jaw Osteonecrosis of the jaw (ONJ) has been reported predominantly in cancer patients treated with intravenous bisphosphonates, including zoledronic acid injection. Many of these patients were also receiving chemotherapy and corticosteroids which may be risk factors for ONJ. The risk of ONJ may increase with duration of exposure to bisphosphonates.
Postmarketing experience and the literature suggest a greater frequency of reports of ONJ based on tumor type (advanced breast cancer, multiple myeloma), and dental status (dental extraction, periodontal disease, local trauma including poorly fitting dentures). Many reports of ONJ involved patients with signs of local infection including osteomyelitis.
Cancer patients should maintain good oral hygiene and should have a dental examination with preventive dentistry prior to treatment with bisphosphonates. While on treatment, these patients should avoid invasive dental procedures if possible. For patients who develop ONJ while on bisphosphonate therapy, dental surgery may exacerbate the condition.
For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of ONJ. Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment [see Adverse Reactions (6.2)].
5.5 Musculoskeletal Pain
5.5 Musculoskeletal Pain In postmarketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported in patients taking bisphosphonates, including zoledronic acid injection. The time to onset of symptoms varied from one day to several months after starting the drug. Discontinue use if severe symptoms develop.
Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate [see Adverse Reactions (6.2)].
5.6 Atypical Subtrochanteric and Diaphyseal Femoral Fractures
5.6 Atypical Subtrochanteric and Diaphyseal Femoral Fractures Atypical subtrochanteric and diaphyseal femoral fractures have been reported in patients receiving bisphosphonate therapy, including zoledronic acid injection. These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to just above the supracondylar flare and are transverse or short oblique in orientation without evidence of comminution.
These fractures occur after minimal or no trauma. Patients may experience thigh or groin pain weeks to months before presenting with a completed femoral fracture. Fractures are often bilateral; therefore the contralateral femur should be examined in bisphosphonate-treated patients who have sustained a femoral shaft fracture.
Poor healing of these fractures has also been reported. A number of case reports noted that patients were also receiving treatment with glucocorticoids (such as prednisone or dexamethasone) at the time of fracture. Causality with bisphosphonate therapy has not been established. Any patient with a history of bisphosphonate exposure who presents with thigh or groin pain in the absence of trauma should be suspected of having an atypical fracture and should be evaluated.
Discontinuation of zoledronic acid injection therapy in patients suspected to have an atypical femur fracture should be considered pending evaluation of the patient, based on an individual benefit risk assessment. It is unknown whether the risk of atypical femur fracture continues after stopping therapy.
5.7 Patients With Asthma
5.7 Patients With Asthma While not observed in clinical trials with zoledronic acid injection, there have been reports of bronchoconstriction in aspirin sensitive patients receiving bisphosphonates.
5.8 Hepatic Impairment
5.8 Hepatic Impairment Only limited clinical data are available for use of zoledronic acid injection to treat hypercalcemia of malignancy in patients with hepatic insufficiency, and these data are not adequate to provide guidance on dosage selection or how to safely use zoledronic acid injection in these patients.
5.9 Hypocalcemia
5.9 Hypocalcemia Hypocalcemia has been reported in patients treated with zoledronic acid injection. Cardiac arrhythmias and neurologic adverse events (seizures, tetany, and numbness) have been reported secondary to cases of severe hypocalcemia. In some instances, hypocalcemia may be life-threatening. Caution is advised when zoledronic acid injection is administered with drugs known to cause hypocalcemia, as severe hypocalcemia may develop, [see Drug Interactions (7)].
Serum calcium should be measured and hypocalcemia must be corrected before initiating zoledronic acid injection. Adequately supplement patients with calcium and vitamin D.
5.10 Embryo-Fetal Toxicity
5.10 Embryo-Fetal Toxicity Based on findings from animal studies and its mechanism of action, zoledronic acid injection can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of zoledronic acid to pregnant rats during organogenesis resulted in fetal malformations and embryo-fetal lethality at maternal exposures that were greater than or equal to 2.4 times the human clinical exposure based on area under the curve (AUC).
Bisphosphonates, such as zoledronic acid injection, are incorporated into the bone matrix, from where they are gradually released over periods of weeks to years. There may be a risk of fetal harm (e.g., skeletal and other abnormalities) if a woman becomes pregnant after completing a course of bisphosphonate therapy. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.
Advise females of reproductive potential to use effective contraception during and after zoledronic acid injection treatment [see Use in Specific Populations (8.1, 8.3), Clinical Pharmacology (12.1)]
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Aminoglycosides, calcitonin, loop diuretics | Adjust or monitor | Additive lowering of calcium (label). | Monitor calcium. |
| Nephrotoxic drugs (NSAIDs, aminoglycosides, others) | Adjust or monitor | More kidney injury (label). | Use with caution; check creatinine. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewed- In-vitro studies indicate that the plasma protein binding of zoledronic acid is low, with the unbound fraction ranging from 60%-77%. In-vitro studies also indicate that zoledronic acid does not inhibit microsomal CYP450 enzymes. In-vivo studies showed that zoledronic acid is not metabolized, and is excreted into the urine as the intact drug. Aminoglycosides: May have an additive effect to lower serum calcium for prolonged periods. (7.1)
- Loop Diuretics: Concomitant use with zoledronic acid injection may increase risk of hypocalcemia. (7.2)
- Nephrotoxic Drugs: Use with caution. (7.3)
7.1 Aminoglycosides and Calcitonin
7.1 Aminoglycosides and Calcitonin Caution is advised when bisphosphonates are administered with aminoglycosides or calcitonin, since these agents may have an additive effect to lower serum calcium level for prolonged periods. This effect has not been reported in zoledronic acid injection clinical trials.
7.2 Loop Diuretics
7.2 Loop Diuretics Caution should also be exercised when zoledronic acid injection is used in combination with loop diuretics due to an increased risk of hypocalcemia.
7.3 Nephrotoxic Drugs
7.3 Nephrotoxic Drugs Caution is indicated when zoledronic acid injection is used with other potentially nephrotoxic drugs.
7.4 Thalidomide
7.4 Thalidomide No dose adjustment for zoledronic acid injection 4 mg is needed when coadministered with thalidomide. In a pharmacokinetic study of 24 patients with multiple myeloma, zoledronic acid injection 4 mg given as a 15 minute infusion was administered either alone or with thalidomide (100 mg once daily on days 1-14 and 200 mg once daily on Days 15-28).
Coadministration of thalidomide with zoledronic acid injection did not significantly change the pharmacokinetics of zoledronic acid or creatinine clearance.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
In-vitro studies also indicate that zoledronic acid does not inhibit microsomal CYP450 enzymes.
Adverse reactions
Common
- Nausea, vomiting, constipation
- Fatigue, fever, bone pain
- Anemia, dyspnea
Serious
- Kidney failure (even at 4 mg over 15 minutes)
- Hypocalcemia, hypophosphatemia, hypomagnesemia
- Osteonecrosis of the jaw
- Atypical femur fracture
- Musculoskeletal pain (can be severe)
- Bronchoconstriction in aspirin-sensitive asthma
- The most common adverse events (greater than 25%) were nausea, fatigue, anemia, bone pain, constipation, fever, vomiting, and dyspnea (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Accord Healthcare Inc. at 1-866-941-7875 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Hypercalcemia of Malignancy The safety of zoledronic acid injection was studied in 185 patients with hypercalcemia of malignancy (HCM) who received either zoledronic acid injection 4 mg given as a 5-minute intravenous infusion (n = 86) or pamidronate 90 mg given as a 2-hour intravenous infusion (n = 103).
The population was aged 33-84 years, 60% male and 81% Caucasian, with breast, lung, head and neck, and renal cancer as the most common forms of malignancy. NOTE: pamidronate 90 mg was given as a 2-hour intravenous infusion. The relative safety of pamidronate 90 mg given as a 2-hour intravenous infusion compared to the same dose given as a 24-hour intravenous infusion has not been adequately studied in controlled clinical trials.
Renal Toxicity Administration of zoledronic acid injection 4 mg given as a 5-minute intravenous infusion has been shown to result in an increased risk of renal toxicity, as measured by increases in serum creatinine, which can progress to renal failure. The incidence of renal toxicity and renal failure has been shown to be reduced when zoledronic acid injection 4 mg is given as a 15-minute intravenous infusion.
Zoledronic Acid Injection should be administered by intravenous infusion over no less than 15 minutes [see Warnings and Precautions (5.3), Dosage and Administration (2.4)]. The most frequently observed adverse events were fever, nausea, constipation, anemia, and dyspnea (see Table 4). Table 4 provides adverse events that were reported by 10% or more of the 189 patients treated with zoledronic acid injection 4 mg or pamidronate 90 mg from the two HCM trials.
Adverse events are listed regardless of presumed causality to study drug. Table 4: Percentage of Patients With Adverse Events Greater Than or Equal to 10% Reported in Hypercalcemia of Malignancy Clinical Trials by Body System Zoledronic Acid Injection 4 mg Pamidronate n (%) 90 mg n (%) Patients Studied Total No. of Patients Studied 86 (100) 103 (100) Total No. of Patients with any AE 81 (94) 95 (92) Body as a Whole Fever 38 (44) 34 (33) Progression of Cancer 14 (16) 21 (20) Cardiovascular Hypotension 9 (11) 2 (2) Digestive Nausea 25 (29) 28 (27) Constipation 23 (27) 13 (13) Diarrhea 15 (17) 17 (17) Abdominal Pain 14 (16) 13 (13) Vomiting 12 (14) 17 (17) Anorexia 8 (9) 14 (14) Hemic and Lymphatic System Anemia 19 (22) 18 (18) Infections Moniliasis 10 (12) 4 (4) Laboratory Abnormalities Hypophosphatemia 11 (13) 2 (2) Hypokalemia 10 (12) 16 (16) Hypomagnesemia 9 (11) 5 (5) Musculoskeletal Skeletal Pain 10 (12) 10 (10) Nervous Insomnia 13 (15) 10 (10) Anxiety 12 (14) 8 (8) Confusion 11 (13) 13 (13) Agitation 11 (13) 8 (8) Respiratory Dyspnea 19 (22) 20 (19) Coughing 10 (12) 12 (12) Urogenital Urinary Tract Infection 12 (14) 15 (15) The following adverse events from the two controlled multicenter HCM trials (n=189) were reported by a greater percentage of patients treated with zoledronic acid injection 4 mg than with pamidronate 90 mg and occurred with a frequency of greater than or equal to 5% but less than 10%.
Adverse events are listed regardless of presumed causality to study drug: asthenia, chest pain, leg edema, mucositis, dysphagia, granulocytopenia, thrombocytopenia, pancytopenia, nonspecific infection, hypocalcemia, dehydration, arthralgias, headache and somnolence. Rare cases of rash, pruritus, and chest pain have been reported following treatment with zoledronic acid injection.
Acute Phase Reaction Within three days after zoledronic acid injection administration, an acute phase reaction has been reported in patients, with symptoms including pyrexia, fatigue, bone pain and/or arthralgias, myalgias, chills, and influenza-like illness. These symptoms usually resolve within a few days. Pyrexia has been the most commonly associated symptom, occurring in 44% of patients.
Mineral and Electrolyte Abnormalities Electrolyte abnormalities, most commonly hypocalcemia, hypophosphatemia and hypomagnesemia, can occur with bisphosphonate use. Grade 3 and Grade 4 laboratory abnormalities for serum creatinine, serum calcium, serum phosphorus, and serum magnesium observed in two clinical trials of zoledronic acid injection in patients with HCM are shown in Table 5 and 6.
Table 5: Grade 3 Laboratory Abnormalities for Serum Creatinine, Serum Calcium, Serum Phosphorus, and Serum Magnesium in Two Clinical Trials in Patients with HCM Laboratory Parameter Grade 3 Zoledronic Acid Injection 4 mg Pamidronate 90 mg n/N (%) n/N (%) Serum Creatinine 1 2/86 (2%) 3/100 (3%) Hypocalcemia 2 1/86 (1%) 2/100 (2%) Hypophosphatemia 3 36/70 (51%) 27/81 (33%) Hypomagnesemia 4 0/71 0 0/84 0 1 Grade 3 (greater than 3x Upper Limit of Normal); Grade 4 (greater than 6x Upper Limit of Normal). 2 Grade 3 (less than 7 mg/dL); Grade 4 (less than 6 mg/dL). 3 Grade 3 (less than 2 mg/dL); Grade 4 (less than 1 mg/dL). 4 Grade 3 (less than 0.8 mEq/L); Grade 4 (less than 0.5 mEq/L). Table 6: Grade 4 Laboratory Abnormalities for Serum Creatinine, Serum Calcium, Serum Phosphorus, and Serum Magnesium in Two Clinical Trials in Patients With HCM Laboratory Parameter Grade 4 Zoledronic Acid Injection 4 mg Pamidronate 90 mg n/N (%) n/N (%) Serum Creatinine 1 0/86 0 1/100 (1%) Hypocalcemia 2 0/86 0 0/100 0 Hypophosphatemia 3 1/70 (1%) 4/81 (5%) Hypomagnesemia 4 0/71 0 1/84 (1%) 1 Grade 3 (greater than 3x Upper Limit of Normal); Grade 4 (greater than 6x Upper Limit of Normal). 2 Grade 3 (less than 7 mg/dL); Grade 4 (less than 6 mg/dL). 3 Grade 3 (less than 2 mg/dL); Grade 4 (less than 1 mg/dL). 4 Grade 3 (less than 0.8 mEq/L); Grade 4 (less than 0.5 mEq/L).
Injection-Site Reactions Local reactions at the infusion-site, such as redness or swelling, were observed infrequently. In most cases, no specific treatment is required and the symptoms subside after 24-48 hours. Ocular Adverse Events Ocular inflammation such as uveitis and scleritis can occur with bisphosphonate use, including zoledronic acid injection.
No cases of iritis, scleritis or uveitis were reported during these clinical trials. However, cases have been seen in postmarketing use [see Adverse Reactions (6.2)]. Multiple Myeloma and Bone Metastases of Solid Tumors The safety analysis includes patients treated in the core and extension phases of the trials. The analysis includes the 2042 patients treated with zoledronic acid injection 4 mg, pamidronate 90 mg, or placebo in the three controlled multicenter bone metastases trials, including 969 patients completing the efficacy phase of the trial, and 619 patients that continued in the safety extension phase.
Only 347 patients completed the extension phases and were followed for 2 years (or 21 months for the other solid tumor patients). The median duration of exposure for safety analysis for zoledronic acid injection 4 mg (core plus extension phases) was 12.8 months for breast cancer and multiple myeloma, 10.8 months for prostate cancer, and 4.0 months for other solid tumors.
Table 7 describes adverse events that were reported by 10% or more of patients. Adverse events are listed regardless of presumed causality to study drug. Table 7: Percentage of Patients With Adverse Events Greater Than or Equal to 10% Reported in Three Bone Metastases Clinical Trials by Body System Zoledronic Acid Injection Pamidronate Placebo 4 mg 90 mg n (%) n (%) n (%) Patients Studied Total No. of Patients 1031 (100) 556 (100) 455 (100) Total No. of Patients with any AE 1015 (98) 548 (99) 445 (98) Blood and Lymphatic Anemia 344 (33) 175 (32) 128 (28) Neutropenia 124 (12) 83 (15) 35 (8) Thrombocytopenia 102 (10) 53 (10) 20 (4) Gastrointestinal Nausea 476 (46) 266 (48) 171 (38) Vomiting 333 (32) 183 (33) 122 (27) Constipation 320 (31) 162 (29) 174 (38) Diarrhea 249 (24) 162 (29) 83 (18) Abdominal Pain 143 (14) 81 (15) 48 (11) Dyspepsia 105 (10) 74 (13) 31 (7) Stomatitis 86 (8) 65 (12) 14 (3) Sore Throat 82 (8) 61 (11) 17 (4) General Disorders and Administration Site Fatigue 398 (39) 240 (43) 130 (29) Pyrexia 328 (32) 172 (31) 89 (20) Weakness 252 (24) 108 (19) 114 (25) Edema Lower Limb 215 (21) 126 (23) 84 (19) Rigors 112 (11) 62 (11) 28 (6) Infections Urinary Tract Infection 124 (12) 50 (9) 41 (9) Upper Respiratory Tract Infection 101 (10) 82 (15) 30 (7) Metabolism Anorexia 231 (22) 81 (15) 105 (23) Weight Decreased 164 (16) 50 (9) 61 (13) Dehydration 145 (14) 60 (11) 59 (13) Appetite Decreased 130 (13) 48 (9) 45 (10) Musculoskeletal Bone Pain 569 (55) 316 (57) 284 (62) Myalgia 239 (23) 143 (26) 74 (16) Arthralgia 216 (21) 131 (24) 73 (16) Back Pain 156 (15) 106 (19) 40 (9) Pain in Limb 143 (14) 84 (15) 52 (11) Neoplasms Malignant Neoplasm Aggravated 205 (20) 97 (17) 89 (20) Nervous Headache 191 (19) 149 (27) 50 (11) Dizziness (excluding vertigo) 180 (18) 91 (16) 58 (13) Insomnia 166 (16) 111 (20) 73 (16) Paresthesia 149 (15) 85 (15) 35 (8) Hypoesthesia 127 (12) 65 (12) 43 (10) Psychiatric Depression 146 (14) 95 (17) 49 (11) Anxiety 112 (11) 73 (13) 37 (8) Confusion 74 (7) 39 (7) 47 (10) Respiratory Dyspnea 282 (27) 155 (28) 107 (24) Cough 224 (22) 129 (23) 65 (14) Skin Alopecia 125 (12) 80 (14) 36 (8) Dermatitis 114 (11) 74 (13) 38 (8) Grade 3 and Grade 4 laboratory abnormalities for serum creatinine, serum calcium, serum phosphorus, and serum magnesium observed in three clinical trials of zoledronic acid injection in patients with bone metastases are shown in Tables 8 and 9.
Table 8: Grade 3 Laboratory Abnormalities for Serum Creatinine, Serum Calcium, Serum Phosphorus, and Serum Magnesium in Three Clinical Trials in Patients With Bone Metastases Grade 3 Laboratory Parameter Zoledronic Acid Injection Pamidronate Placebo 4 mg 90 mg n/N (%) n/N (%) n/N (%) Serum Creatinine 1* 7/529 (1%) 4/268 (2%) 4/241 (2%) Hypocalcemia 2 6/973 (< 1%) 4/536 (< 1%) 0/415 0 Hypophosphatemia 3 115/973 (12%) 38/537 (7%) 14/415 (3%) Hypermagnesemia 4 19/971 (2%) 2/535 (< 1%) 8/415 (2%) Hypomagnesemia 5 1/971 (< 1%) 0/535 — 1/415 (< 1%) * Serum creatinine data for all patients randomized after the 15 -minute infusion amendment. 1 Grade 3 (greater than 3x Upper Limit of Normal); Grade 4 (greater than 6x Upper Limit of Normal). 2 Grade 3 (less than 7 mg/dL); Grade 4 (less than 6 mg/dL). 3 Grade 3 (less than 2 mg/dL); Grade 4 (less than 1 mg/dL). 4 Grade 3 (greater than 3 mEq/L); Grade 4 (greater than 8 mEq/L). 5 Grade 3 (less than 0.9 mEq/L); Grade 4 (less than 0.7 mEq/L). Table 9: Grade 4 Laboratory Abnormalities for Serum Creatinine, Serum Calcium, Serum Phosphorus, and Serum Magnesium in Three Clinical Trials in Patients With Bone Metastases Grade 4 Laboratory Parameter Zoledronic Acid Injection Pamidronate Placebo 4 mg 90 mg n/N (%) n/N (%) n/N (%) Serum Creatinine 1* 2/529 (< 1%) 1/268 (< 1%) 0/241 0 Hypocalcemia 2 7/973 (< 1%) 3/536 (< 1%) 2/415 (< 1%) Hypophosphatemia 3 5/973 (< 1%) 0/537 0 1/415 (< 1%) Hypermagnesemia 4 0/971 0 0/535 0 2/415 (< 1%) Hypomagnesemia 5 2/971 (< 1%) 1/535 (< 1%) 0/415 0 * Serum creatinine data for all patients randomized after the 15-minute infusion amendment. 1 Grade 3 (greater than 3x Upper Limit of Normal); Grade 4 (greater than 6x Upper Limit of Normal). 2 Grade 3 (less than 7 mg/dL); Grade 4 (less than 6 mg/dL). 3 Grade 3 (less than 2 mg/dL); Grade 4 (less than 1 mg/dL). 4 Grade 3 (greater than 3 mEq/L); Grade 4 (greater than 8 mEq/L). 5 Grade 3 (less than 0.9 mEq/L); Grade 4 (less than 0.7 mEq/L).
Among the less frequently occurring adverse events (less than 15% of patients), rigors, hypokalemia, influenza-like illness, and hypocalcemia showed a trend for more events with bisphosphonate administration (zoledronic acid injection 4 mg and pamidronate groups) compared to the placebo group. Less common adverse events reported more often with zoledronic acid injection 4 mg than pamidronate included decreased weight, which was reported in 16% of patients in the zoledronic acid injection 4 mg group compared with 9% in the pamidronate group.
Decreased appetite was reported in slightly more patients in the zoledronic acid injection 4 mg group (13%) compared with the pamidronate (9%) and placebo (10%) groups, but the clinical significance of these small differences is not clear. Renal Toxicity In the bone metastases trials, renal deterioration was defined as an increase of 0.5 mg/dL for patients with normal baseline creatinine (less than 1.4 mg/dL) or an increase of 1.0 mg/dL for patients with an abnormal baseline creatinine (greater than or equal to1.4 mg/dL).
The following are data on the incidence of renal deterioration in patients receiving zoledronic acid injection 4 mg over 15 minutes in these trials (see Table 10). Table 10: Percentage of Patients With Treatment Emergent Renal Function Deterioration by Baseline Serum Creatinine* Patient Population/Baseline Creatinine Multiple Myeloma and Breast Cancer Zoledronic Acid Injection 4 mg Pamidronate 90 mg n/N (%) n/N (%) Normal 27/246 (11%) 23/246 (9%) Abnormal 2/26 (8%) 2/22 (9%) Total 29/272 (11%) 25/268 (9%) Solid Tumors Zoledronic Acid Injection 4 mg Placebo n/N (%) n/N (%) Normal 17/154 (11%) 10/143 (7%) Abnormal 1/11 (9%) 1/20 (5%) Total 18/165 (11%) 11/163 (7%) Prostate Cancer Zoledronic Acid Injection 4 mg Placebo n/N (%) n/N (%) Normal 12/82 (15%) 8/68 (12%) Abnormal 4/10 (40%) 2/10 (20%) Total 16/92 (17%) 10/78 (13%) * Table includes only patients who were randomized to the trial after a protocol amendment that lengthened the infusion duration of zoledronic acid injection to 15 minutes.
The risk of deterioration in renal function appeared to be related to time on study, whether patients were receiving zoledronic acid injection (4 mg over 15 minutes), placebo, or pamidronate. In the trials and in postmarketing experience, renal deterioration, progression to renal failure and dialysis have occurred in patients with normal and abnormal baseline renal function, including patients treated with 4 mg infused over a 15-minute period.
There have been instances of this occurring after the initial zoledronic acid injection dose.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been reported during postapproval use of zoledronic acid injection. Because these reports are from a population of uncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Osteonecrosis of the Jaw Cases of osteonecrosis (primarily involving the jaw but also of other anatomical sites including hip, femur and external auditory canal) have been reported predominantly in cancer patients treated with intravenous bisphosphonates including zoledronic acid injection. Many of these patients were also receiving chemotherapy and corticosteroids which may be a risk factor for ONJ.
Caution is advised when zoledronic acid injection is administered with anti-angiogenic drugs as an increased incidence of ONJ has been observed with concomitant use of these drugs. Data suggests a greater frequency of reports of ONJ in certain cancers, such as advanced breast cancer and multiple myeloma. The majority of the reported cases are in cancer patients following invasive dental procedures, such as tooth extraction.
It is therefore prudent to avoid invasive dental procedures as recovery may be prolonged [see Warnings and Precautions (5.4)]. Acute Phase Reaction Within three days after zoledronic acid injection administration, an acute phase reaction has been reported, with symptoms including pyrexia, fatigue, bone pain and/or arthralgias, myalgias, chills, influenza-like illness and arthritis with subsequent joint swelling; these symptoms usually resolve within three days of onset, but resolution could take up to 7 to 14 days.
However, some of these symptoms have been reported to persist for a longer duration. Musculoskeletal Pain Severe and occasionally incapacitating bone, joint, and/or muscle pain has been reported with bisphosphonate use [see Warnings and Precautions (5.5)]. Atypical Subtrochanteric and Diaphyseal Femoral Fractures Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, including zoledronic acid injection [see Warnings and Precautions (5.6)].
Ocular Adverse Events Cases of uveitis, scleritis, episcleritis, conjunctivitis, iritis, and orbital inflammation including orbital edema have been reported during postmarketing use. In some cases, symptoms resolved with topical steroids. Hypersensitivity Reactions There have been rare reports of allergic reaction with intravenous zoledronic acid including angioedema and bronchoconstriction.
Very rare cases of anaphylactic reaction/shock have been reported. Cases of Stevens-Johnson syndrome and toxic epidermal necrolysis have also been reported. Additional adverse reactions reported in postmarketing use include: CNS: taste disturbance, hyperesthesia, tremor; Special Senses: blurred vision; uveitis; Gastrointestinal: dry mouth; Skin: Increased sweating; Musculoskeletal: muscle cramps; Cardiovascular: hypertension, bradycardia, hypotension (associated with syncope or circulatory collapse primarily in patients with underlying risk factors); Respiratory: bronchospasms, interstitial lung disease (ILD) with positive rechallenge; Renal: hematuria, proteinuria, acquired Fanconi syndrome; General Disorders and Administration Site: weight increase, influenza-like illness (pyrexia, asthenia, fatigue or malaise) persisting for greater than 30 days; Laboratory Abnormalities: hyperkalemia, hypernatremia, hypocalcemia (cardiac arrhythmias and neurologic adverse events including seizures, tetany, and numbness have been reported due to severe hypocalcemia).
Adverse reaction frequency tables (US label) US FDA label
| Zoledronic Acid Injection 4 mg | Pamidronate | |||
| n (%) | 90 mg | |||
| n (%) | ||||
| Patients Studied | ||||
| Total No. of Patients Studied | 86 | (100) | 103 | (100) |
| Total No. of Patients with any AE | 81 | (94) | 95 | (92) |
| Body as a Whole | ||||
| Fever | 38 | (44) | 34 | (33) |
| Progression of Cancer | 14 | (16) | 21 | (20) |
| Cardiovascular | ||||
| Hypotension | 9 | (11) | 2 | (2) |
| Digestive | ||||
| Nausea | 25 | (29) | 28 | (27) |
| Constipation | 23 | (27) | 13 | (13) |
| Diarrhea | 15 | (17) | 17 | (17) |
| Abdominal Pain | 14 | (16) | 13 | (13) |
| Vomiting | 12 | (14) | 17 | (17) |
| Anorexia | 8 | (9) | 14 | (14) |
| Hemic and Lymphatic System | ||||
| Anemia | 19 | (22) | 18 | (18) |
| Infections | ||||
| Moniliasis | 10 | (12) | 4 | (4) |
| Laboratory Abnormalities | ||||
| Hypophosphatemia | 11 | (13) | 2 | (2) |
| Hypokalemia | 10 | (12) | 16 | (16) |
| Hypomagnesemia | 9 | (11) | 5 | (5) |
| Musculoskeletal | ||||
| Skeletal Pain | 10 | (12) | 10 | (10) |
| Nervous | ||||
| Insomnia | 13 | (15) | 10 | (10) |
| Anxiety | 12 | (14) | 8 | (8) |
| Confusion | 11 | (13) | 13 | (13) |
| Agitation | 11 | (13) | 8 | (8) |
| Respiratory | ||||
| Dyspnea | 19 | (22) | 20 | (19) |
| Coughing | 10 | (12) | 12 | (12) |
| Urogenital | ||||
| Urinary Tract Infection | 12 | (14) | 15 | (15) |
| Laboratory Parameter | Grade 3 | |||
| Zoledronic Acid Injection 4 mg | Pamidronate 90 mg | |||
| n/N | (%) | n/N | (%) | |
| Serum Creatinine 1 | 2/86 | (2%) | 3/100 | (3%) |
| Hypocalcemia 2 | 1/86 | (1%) | 2/100 | (2%) |
| Hypophosphatemia 3 | 36/70 | (51%) | 27/81 | (33%) |
| Hypomagnesemia 4 | 0/71 | 0 | 0/84 | 0 |
| 1Grade 3 (greater than 3x Upper Limit of Normal); Grade 4 (greater than 6x Upper Limit of Normal). 2Grade 3 (less than 7 mg/dL); Grade 4 (less than 6 mg/dL). 3Grade 3 (less than 2 mg/dL); Grade 4 (less than 1 mg/dL). 4Grade 3 (less than 0.8 mEq/L); Grade 4 (less than 0.5 mEq/L). | ||||
| Laboratory Parameter | Grade 4 | |||
| Zoledronic Acid Injection 4 mg | Pamidronate 90 mg | |||
| n/N | (%) | n/N | (%) | |
| Serum Creatinine 1 | 0/86 | 0 | 1/100 | (1%) |
| Hypocalcemia 2 | 0/86 | 0 | 0/100 | 0 |
| Hypophosphatemia 3 | 1/70 | (1%) | 4/81 | (5%) |
| Hypomagnesemia 4 | 0/71 | 0 | 1/84 | (1%) |
| 1Grade 3 (greater than 3x Upper Limit of Normal); Grade 4 (greater than 6x Upper Limit of Normal). 2Grade 3 (less than 7 mg/dL); Grade 4 (less than 6 mg/dL). 3Grade 3 (less than 2 mg/dL); Grade 4 (less than 1 mg/dL). 4Grade 3 (less than 0.8 mEq/L); Grade 4 (less than 0.5 mEq/L). | ||||
| Zoledronic Acid Injection | Pamidronate | Placebo | ||||
| 4 mg | 90 mg | |||||
| n (%) | n (%) | n (%) | ||||
| Patients Studied | ||||||
| Total No. of Patients | 1031 | (100) | 556 | (100) | 455 | (100) |
| Total No. of Patients with any AE | 1015 | (98) | 548 | (99) | 445 | (98) |
| Blood and Lymphatic | ||||||
| Anemia | 344 | (33) | 175 | (32) | 128 | (28) |
| Neutropenia | 124 | (12) | 83 | (15) | 35 | (8) |
| Thrombocytopenia | 102 | (10) | 53 | (10) | 20 | (4) |
| Gastrointestinal | ||||||
| Nausea | 476 | (46) | 266 | (48) | 171 | (38) |
| Vomiting | 333 | (32) | 183 | (33) | 122 | (27) |
| Constipation | 320 | (31) | 162 | (29) | 174 | (38) |
| Diarrhea | 249 | (24) | 162 | (29) | 83 | (18) |
| Abdominal Pain | 143 | (14) | 81 | (15) | 48 | (11) |
| Dyspepsia | 105 | (10) | 74 | (13) | 31 | (7) |
| Stomatitis | 86 | (8) | 65 | (12) | 14 | (3) |
| Sore Throat | 82 | (8) | 61 | (11) | 17 | (4) |
| General Disorders and Administration Site | ||||||
| Fatigue | 398 | (39) | 240 | (43) | 130 | (29) |
| Pyrexia | 328 | (32) | 172 | (31) | 89 | (20) |
| Weakness | 252 | (24) | 108 | (19) | 114 | (25) |
| Edema Lower Limb | 215 | (21) | 126 | (23) | 84 | (19) |
| Rigors | 112 | (11) | 62 | (11) | 28 | (6) |
| Infections | ||||||
| Urinary Tract Infection | 124 | (12) | 50 | (9) | 41 | (9) |
| Upper Respiratory Tract Infection | 101 | (10) | 82 | (15) | 30 | (7) |
| Metabolism | ||||||
| Anorexia | 231 | (22) | 81 | (15) | 105 | (23) |
| Weight Decreased | 164 | (16) | 50 | (9) | 61 | (13) |
| Dehydration | 145 | (14) | 60 | (11) | 59 | (13) |
| Appetite Decreased | 130 | (13) | 48 | (9) | 45 | (10) |
| Musculoskeletal | ||||||
| Bone Pain | 569 | (55) | 316 | (57) | 284 | (62) |
| Myalgia | 239 | (23) | 143 | (26) | 74 | (16) |
| Arthralgia | 216 | (21) | 131 | (24) | 73 | (16) |
| Back Pain | 156 | (15) | 106 | (19) | 40 | (9) |
| Pain in Limb | 143 | (14) | 84 | (15) | 52 | (11) |
| Neoplasms | ||||||
| Malignant Neoplasm Aggravated | 205 | (20) | 97 | (17) | 89 | (20) |
| Nervous | ||||||
| Headache | 191 | (19) | 149 | (27) | 50 | (11) |
| Dizziness (excluding vertigo) | 180 | (18) | 91 | (16) | 58 | (13) |
| Insomnia | 166 | (16) | 111 | (20) | 73 | (16) |
| Paresthesia | 149 | (15) | 85 | (15) | 35 | (8) |
| Hypoesthesia | 127 | (12) | 65 | (12) | 43 | (10) |
| Psychiatric | ||||||
| Depression | 146 | (14) | 95 | (17) | 49 | (11) |
| Anxiety | 112 | (11) | 73 | (13) | 37 | (8) |
| Confusion | 74 | (7) | 39 | (7) | 47 | (10) |
| Respiratory | ||||||
| Dyspnea | 282 | (27) | 155 | (28) | 107 | (24) |
| Cough | 224 | (22) | 129 | (23) | 65 | (14) |
| Skin | ||||||
| Alopecia | 125 | (12) | 80 | (14) | 36 | (8) |
| Dermatitis | 114 | (11) | 74 | (13) | 38 | (8) |
| Grade 3 | ||||||
| Laboratory Parameter | Zoledronic Acid Injection | Pamidronate | Placebo | |||
| 4 mg | 90 mg | |||||
| n/N | (%) | n/N | (%) | n/N | (%) | |
| Serum Creatinine1* | 7/529 | (1%) | 4/268 | (2%) | 4/241 | (2%) |
| Hypocalcemia2 | 6/973 | (< 1%) | 4/536 | (< 1%) | 0/415 | 0 |
| Hypophosphatemia3 | 115/973 | (12%) | 38/537 | (7%) | 14/415 | (3%) |
| Hypermagnesemia4 | 19/971 | (2%) | 2/535 | (< 1%) | 8/415 | (2%) |
| Hypomagnesemia5 | 1/971 | (< 1%) | 0/535 | — | 1/415 | (< 1%) |
| *Serum creatinine data for all patients randomized after the 15 -minute infusion amendment. 1Grade 3 (greater than 3x Upper Limit of Normal); Grade 4 (greater than 6x Upper Limit of Normal). 2Grade 3 (less than 7 mg/dL); Grade 4 (less than 6 mg/dL). 3Grade 3 (less than 2 mg/dL); Grade 4 (less than 1 mg/dL). 4Grade 3 (greater than 3 mEq/L); Grade 4 (greater than 8 mEq/L). 5Grade 3 (less than 0.9 mEq/L); Grade 4 (less than 0.7 mEq/L). | ||||||
| Grade 4 | ||||||
| Laboratory Parameter | Zoledronic Acid Injection | Pamidronate | Placebo | |||
| 4 mg | 90 mg | |||||
| n/N | (%) | n/N | (%) | n/N | (%) | |
| Serum Creatinine1* | 2/529 | (< 1%) | 1/268 | (< 1%) | 0/241 | 0 |
| Hypocalcemia2 | 7/973 | (< 1%) | 3/536 | (< 1%) | 2/415 | (< 1%) |
| Hypophosphatemia3 | 5/973 | (< 1%) | 0/537 | 0 | 1/415 | (< 1%) |
| Hypermagnesemia4 | 0/971 | 0 | 0/535 | 0 | 2/415 | (< 1%) |
| Hypomagnesemia5 | 2/971 | (< 1%) | 1/535 | (< 1%) | 0/415 | 0 |
| *Serum creatinine data for all patients randomized after the 15-minute infusion amendment. 1Grade 3 (greater than 3x Upper Limit of Normal); Grade 4 (greater than 6x Upper Limit of Normal). 2Grade 3 (less than 7 mg/dL); Grade 4 (less than 6 mg/dL). 3Grade 3 (less than 2 mg/dL); Grade 4 (less than 1 mg/dL). 4Grade 3 (greater than 3 mEq/L); Grade 4 (greater than 8 mEq/L). 5Grade 3 (less than 0.9 mEq/L); Grade 4 (less than 0.7 mEq/L). | ||||||
| Patient Population/Baseline Creatinine | ||||
| Multiple Myeloma and Breast Cancer | Zoledronic Acid Injection 4 mg | Pamidronate 90 mg | ||
| n/N | (%) | n/N | (%) | |
| Normal | 27/246 | (11%) | 23/246 | (9%) |
| Abnormal | 2/26 | (8%) | 2/22 | (9%) |
| Total | 29/272 | (11%) | 25/268 | (9%) |
| Solid Tumors | Zoledronic Acid Injection 4 mg | Placebo | ||
| n/N | (%) | n/N | (%) | |
| Normal | 17/154 | (11%) | 10/143 | (7%) |
| Abnormal | 1/11 | (9%) | 1/20 | (5%) |
| Total | 18/165 | (11%) | 11/163 | (7%) |
| Prostate Cancer | Zoledronic Acid Injection 4 mg | Placebo | ||
| n/N | (%) | n/N | (%) | |
| Normal | 12/82 | (15%) | 8/68 | (12%) |
| Abnormal | 4/10 | (40%) | 2/10 | (20%) |
| Total | 16/92 | (17%) | 10/78 | (13%) |
| *Table includes only patients who were randomized to the trial after a protocol amendment that lengthened the infusion duration of zoledronic acid injection to 15 minutes. | ||||
Monitoring parameters
- Serum creatinine before every dose; calcium, phosphate, magnesium; hydration before infusion (no diuretic before hypovolemia is corrected). Dental examination (osteonecrosis of the jaw). Thigh or groin pain (atypical femur fracture). Kidney
- Serum creatinine before every dose
- Calcium, phosphate, magnesium
- Dental status
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, Zoledronic Acid Injection can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data in pregnant women to inform the drug-associated risk. In animal reproduction studies, administration of zoledronic acid to pregnant rats during organogenesis resulted in fetal malformations and embryo-fetal lethality at maternal exposures that were ≥ 2.4 times the human clinical exposure based on AUC (see Data).
Bisphosphonates, such as zoledronic acid injection, are incorporated into the bone matrix, from where they are gradually released over periods of weeks to years. There may be a risk of fetal harm (e.g., skeletal and other abnormalities) if a woman becomes pregnant after completing a course of bisphosphonate therapy. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.
The background risk of major birth defects and miscarriage for the indicated population is unknown; however, in the U.S. general population, the estimated background risk of major birth defects is 2%-4% and of miscarriage is 15%-20% of clinically recognized pregnancies.
Mechanism of action
12.1 Mechanism of Action The principal pharmacologic action of zoledronic acid is inhibition of bone resorption. Although the antiresorptive mechanism is not completely understood, several factors are thought to contribute to this action. In vitro, zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis. Zoledronic acid also blocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Zoledronic acid inhibits the increased osteoclastic activity and skeletal calcium release induced by various stimulatory factors released by tumors.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Clinical studies in patients with hypercalcemia of malignancy (HCM) showed that single-dose infusions of zoledronic acid injection are associated with decreases in serum calcium and phosphorus and increases in urinary calcium and phosphorus excretion. Osteoclastic hyperactivity resulting in excessive bone resorption is the underlying pathophysiologic derangement in hypercalcemia of malignancy (HCM, tumor-induced hypercalcemia) and metastatic bone disease.
Excessive release of calcium into the blood as bone is resorbed results in polyuria and gastrointestinal disturbances, with progressive dehydration and decreasing glomerular filtration rate. This, in turn, results in increased renal resorption of calcium, setting up a cycle of worsening systemic hypercalcemia. Reducing excessive bone resorption and maintaining adequate fluid administration are, therefore, essential to the management of hypercalcemia of malignancy.
Patients who have hypercalcemia of malignancy can generally be divided into two groups according to the pathophysiologic mechanism involved: humoral hypercalcemia and hypercalcemia due to tumor invasion of bone. In humoral hypercalcemia, osteoclasts are activated and bone resorption is stimulated by factors such as parathyroid hormone-related protein, which are elaborated by the tumor and circulate systemically.
Humoral hypercalcemia usually occurs in squamous cell malignancies of the lung or head and neck or in genitourinary tumors such as renal cell carcinoma or ovarian cancer. Skeletal metastases may be absent or minimal in these patients. Extensive invasion of bone by tumor cells can also result in hypercalcemia due to local tumor products that stimulate bone resorption by osteoclasts.
Tumors commonly associated with locally mediated hypercalcemia include breast cancer and multiple myeloma. Total serum calcium levels in patients who have hypercalcemia of malignancy may not reflect the severity of hypercalcemia, since concomitant hypoalbuminemia is commonly present. Ideally, ionized calcium levels should be used to diagnose and follow hypercalcemic conditions; however, these are not commonly or rapidly available in many clinical situations.
Therefore, adjustment of the total serum calcium value for differences in albumin levels (corrected serum calcium, CSC) is often used in place of measurement of ionized calcium; several nomograms are in use for this type of calculation [see Dosage and Administration (2.1)].
Pharmacokinetics
Key PK parameters
| Half-life | Triphasic: 0.24 and 1.87 hours early; terminal about 146 hours |
|---|---|
| Half-life in kidney failure (ESKD) kidney | AUC doubled at CrCl 10 mL/min (model; label) |
| Protein binding | Low (unbound 60% to 77%) |
| Metabolism (CYP, transporters) | Not metabolized |
| Active metabolites | None |
| Renal excretion kidney | About 39% ± 16% of dose in urine within 24 hours; rest bound to bone |
| Dialyzability kidney | Not stated |
The terminal elimination phase of zoledronic acid was prolonged, with very low concentrations in plasma between Days 2 and 28 postinfusion, and a terminal elimination half-life t 1/2γ of 146 hours.
Excretion In 64 patients with cancer and bone metastases, on average (± SD) 39 ± 16% of the administered zoledronic acid dose was recovered in the urine within 24 hours, with only trace amounts of drug found in urine post-Day 2.
The cumulative percent of drug excreted in the urine over 0-24 hours was independent of dose.
The 0-24 hour renal clearance of zoledronic acid was 3.7 ± 2.0 L/h.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Pharmacokinetic data in patients with hypercalcemia are not available. Distribution Single or multiple (every 28 days) 5-minute or 15-minute infusions of 2, 4, 8 or 16 mg zoledronic acid injection were given to 64 patients with cancer and bone metastases. The post-infusion decline of zoledronic acid concentrations in plasma was consistent with a triphasic process showing a rapid decrease from peak concentrations at end of infusion to less than 1% of C max 24 hours postinfusion with population half-lives of t 1/2α 0.24 hours and t 1/2β 1.87 hours for the early disposition phases of the drug.
The terminal elimination phase of zoledronic acid was prolonged, with very low concentrations in plasma between Days 2 and 28 postinfusion, and a terminal elimination half-life t 1/2γ of 146 hours. The area under the plasma concentration versus time curve (AUC 0-24h) of zoledronic acid was dose proportional from 2-16 mg.
The accumulation of zoledronic acid measured over three cycles was low, with mean AUC 0-24h ratios for cycles 2 and 3 versus 1 of 1.13 ± 0.30 and 1.16 ± 0.36, respectively. In vitro and ex vivo studies showed low affinity of zoledronic acid for the cellular components of human blood, with a mean blood to plasma concentration ratio of 0.59 in a concentration range of 30 ng/mL to 5000 ng/mL.
In vitro, the plasma protein binding is low, with the unbound fraction ranging from 60% at 2 ng/mL to 77% at 2000 ng/mL of zoledronic acid. Metabolism Zoledronic acid does not inhibit human P450 enzymes in vitro. Zoledronic acid does not undergo biotransformation in vivo. In animal studies, less than 3% of the administered intravenous dose was found in the feces, with the balance either recovered in the urine or taken up by bone, indicating that the drug is eliminated intact via the kidney.
Following an intravenous dose of 20 nCi 14 C-zoledronic acid in a patient with cancer and bone metastases, only a single radioactive species with chromatographic properties identical to those of parent drug was recovered in urine, which suggests that zoledronic acid is not metabolized. Excretion In 64 patients with cancer and bone metastases, on average (± SD) 39 ± 16% of the administered zoledronic acid dose was recovered in the urine within 24 hours, with only trace amounts of drug found in urine post-Day 2.
The cumulative percent of drug excreted in the urine over 0-24 hours was independent of dose. The balance of drug not recovered in urine over 0-24 hours, representing drug presumably bound to bone, is slowly released back into the systemic circulation, giving rise to the observed prolonged low plasma concentrations. The 0-24 hour renal clearance of zoledronic acid was 3.7 ± 2.0 L/h.
Zoledronic acid clearance was independent of dose but dependent upon the patient’s creatinine clearance. In a study in patients with cancer and bone metastases, increasing the infusion time of a 4-mg dose of zoledronic acid from 5 minutes (n = 5) to 15 minutes (n = 7) resulted in a 34% decrease in the zoledronic acid concentration at the end of the infusion ([mean ± SD] 403 ± 118 ng/mL versus 264 ± 86 ng/mL) and a 10% increase in the total AUC (378 ± 116 ng x h/mL versus 420 ± 218 ng x h/mL).
The difference between the AUC means was not statistically significant. Special Populations Pediatrics Zoledronic Acid Injection is not indicated for use in children [see Use in Specific Populations (8.4)]. Geriatrics The pharmacokinetics of zoledronic acid were not affected by age in patients with cancer and bone metastases who ranged in age from 38 years to 84 years.
Race Population pharmacokinetic analyses did not indicate any differences in pharmacokinetics among Japanese and North American (Caucasian and African American) patients with cancer and bone metastases. Hepatic Insufficiency No clinical studies were conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of zoledronic acid.
Renal Insufficiency The pharmacokinetic studies conducted in 64 cancer patients represented typical clinical populations with normal to moderately impaired renal function. Compared to patients with normal renal function (N = 37), patients with mild renal impairment (N = 15) showed an average increase in plasma AUC of 15%, whereas patients with moderate renal impairment (N = 11) showed an average increase in plasma AUC of 43%.
Limited pharmacokinetic data are available for zoledronic acid injection in patients with severe renal impairment (creatinine clearance less than 30 mL/min). Based on population PK/PD modeling, the risk of renal deterioration appears to increase with AUC, which is doubled at a creatinine clearance of 10 mL/min. Creatinine clearance is calculated by the Cockcroft-Gault formula: CrCl = [140-age (years)] x weight (kg) {x 0.85 for female patients} [72 x serum creatinine (mg/dL)] Zoledronic Acid Injection systemic clearance in individual patients can be calculated from the population clearance of zoledronic acid injection, CL (L/h)=6.5(CrCl/90) 0.4.
These formulae can be used to predict the zoledronic acid injection AUC in patients, where CL = Dose/AUC 0-∞. The average AUC 0-24 in patients with normal renal function was 0.42 mg•h/L and the calculated AUC 0-∞ for a patient with creatinine clearance of 75 mL/min was 0.66 mg•h/L following a 4-mg dose of zoledronic acid injection.
However, efficacy and safety of adjusted dosing based on these formulae have not been prospectively assessed [see Warnings and Precautions (5.3)].
Formulary and pricing (Philippines)
Formulary and coverage
| Philippine National Formulary | Listed as Zoledronic Acid |
| PNF listing | Inj.: 4mg/5mL concentrated solution for IV Infusion |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Zoledronic acid · Accord Healthcare Inc. [US FDA-approved label, version 7, October 8, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3df715a1-2562-4374-a383-6edc33c6e52f
- U.S. Food and Drug Administration. Reclast · Sandoz Inc [US FDA-approved label, version 3, February 3, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9b3737-9ce6-4a89-b76e-6aab79eba9cf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- Accord Healthcare Inc. (2025). Zoledronic acid injection 4 mg/5 mL (oncology) [Prescribing information; US FDA-approved label, ANDA205279, set ID 3df715a1-2562-4374-a383-6edc33c6e52f, version effective October 8, 2025]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3df715a1-2562-4374-a383-6edc33c6e52f
- Sandoz Inc. (2026). RECLAST (zoledronic acid) injection 5 mg/100 mL [Prescribing information; US FDA-approved label, NDA021817, set ID 5a9b3737-9ce6-4a89-b76e-6aab79eba9cf, version effective February 3, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9b3737-9ce6-4a89-b76e-6aab79eba9cf
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .
US label: 5 mg/100 mL (osteoporosis, Paget's disease)
Indications and usage (US label) US FDA label
1 INDICATIONS AND USAGE Reclast is a bisphosphonate indicated for:
- Treatment and prevention of postmenopausal osteoporosis (1.1, 1.2)
- Treatment to increase bone mass in men with osteoporosis (1.3)
- Treatment and prevention of glucocorticoid-induced osteoporosis (1.4)
- Treatment of Paget’s disease of bone in men and women (1.5) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use (1.6) 1.1 Treatment of Osteoporosis in Postmenopausal Women Reclast is indicated for treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, diagnosed by bone mineral density (BMD) or prevalent vertebral fracture, Reclast reduces the incidence of fractures (hip, vertebral, and non-vertebral osteoporosis-related fractures). In patients at high risk of fracture, defined as a recent low-trauma hip fracture, Reclast reduces the incidence of new clinical fractures [see Clinical Studies (14.1)]. 1.2 Prevention of Osteoporosis in Postmenopausal Women Reclast is indicated for prevention of osteoporosis in postmenopausal women [see Clinical Studies (14.2)]. 1.3 Osteoporosis in Men Reclast is indicated for treatment to increase bone mass in men with osteoporosis [see Clinical Studies (14.3)]. 1.4 Glucocorticoid-Induced Osteoporosis Reclast is indicated for the treatment and prevention of glucocorticoid-induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months [see Clinical Studies (14.4)]. 1.5 Paget's Disease of Bone Reclast is indicated for treatment of Paget's disease of bone in men and women. Treatment is indicated in patients with Paget’s disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease [see Clinical Studies (14.5)]. 1.6 Important Limitations of Use The safety and effectiveness of Reclast for the treatment of osteoporosis is based on clinical data of three years duration. The optimal duration of use has not been determined. All patients on bisphosphonate therapy should have the need for continued therapy reevaluated on a periodic basis. Patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for fracture reevaluated periodically.
- Infusion given intravenously over no less than 15 minutes: • Treatment of postmenopausal osteoporosis (2.2); treatment to increase bone mass in men with osteoporosis (2.4): treatment and prevention of glucocorticoid-induced osteoporosis (2.5): 5 mg once a year • Prevention of postmenopausal osteoporosis: 5 mg once every 2 years (2.3)
- • Treatment of Paget’s disease of bone: a single 5 mg infusion. Patients should receive 1500 mg elemental calcium and 800 international units vitamin D daily (2.6)
2.1 Important Administration Instructions
2.1 Important Administration Instructions Reclast injection must be administered as an intravenous infusion over no less than 15 minutes.
- Patients must be appropriately hydrated prior to administration of Reclast [see Warnings and Precautions (5.3)].
- Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
- Intravenous infusion should be followed by a 10 mL normal saline flush of the intravenous line.
- Administration of acetaminophen following Reclast administration may reduce the incidence of acute-phase reaction symptoms.
2.2 Treatment of Osteoporosis in Postmenopausal Women
2.2 Treatment of Osteoporosis in Postmenopausal Women The recommended regimen is a 5 mg infusion once a year given intravenously over no less than 15 minutes.
2.3 Prevention of Osteoporosis in Postmenopausal Women
2.3 Prevention of Osteoporosis in Postmenopausal Women The recommended regimen is a 5 mg infusion given once every 2 years intravenously over no less than 15 minutes.
2.4 Osteoporosis in Men
2.4 Osteoporosis in Men The recommended regimen is a 5 mg infusion once a year given intravenously over no less than 15 minutes.
2.5 Treatment and Prevention of Glucocorticoid-Induced Osteoporosis
2.5 Treatment and Prevention of Glucocorticoid-Induced Osteoporosis The recommended regimen is a 5 mg infusion once a year given intravenously over no less than 15 minutes.
2.6 Treatment of Paget’s Disease of Bone
2.6 Treatment of Paget’s Disease of Bone The recommended dose is a 5 mg infusion. The infusion time must not be less than 15 minutes given over a constant infusion rate. Re-treatment of Paget’s Disease After a single treatment with Reclast in Paget’s disease an extended remission period is observed. Specific re-treatment data are not available.
However, re-treatment with Reclast may be considered in patients who have relapsed, based on increases in serum alkaline phosphatase, or in those patients who failed to achieve normalization of their serum alkaline phosphatase, or in those patients with symptoms, as dictated by medical practice.
2.7 Laboratory Testing and Oral Examination Prior to Administration
2.7 Laboratory Testing and Oral Examination Prior to Administration
- Prior to administration of each dose of Reclast, obtain a serum creatinine and creatinine clearance should be calculated based on actual body weight using Cockcroft-Gault formula before each Reclast dose. Reclast is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment. A 5 mg dose of Reclast administered intravenously is recommended for patients with creatinine clearance greater than or equal to 35 mL/min. There are no safety or efficacy data to support the adjustment of the Reclast dose based on baseline renal function. Therefore, no dose adjustment is required in patients with creatinine clearance greater than or equal to 35 mL/min [see Contraindications (4), Warnings and Precautions (5.3)].
- A routine oral examination should be performed by the prescriber prior to initiation of Reclast treatment [see Warnings and Precautions (5.4)].
2.8 Calcium and Vitamin D Supplementation
2.8 Calcium and Vitamin D Supplementation
- Instruct patients being treated for Paget’s disease of bone on the importance of calcium and vitamin D supplementation in maintaining serum calcium levels, and on the symptoms of hypocalcemia. All patients should take 1500 mg elemental calcium daily in divided doses (750 mg two times a day, or 500 mg three times a day) and 800 international units vitamin D daily, particularly in the 2 weeks following Reclast administration [see Warnings and Precautions (5.2)].
- Instruct patients being treated for osteoporosis to take supplemental calcium and vitamin D if their dietary intake is inadequate. An average of at least 1200 mg calcium and 800-1000 international units vitamin D daily is recommended.
2.9 Method of Administration
2.9 Method of Administration The Reclast infusion time must not be less than 15 minutes given over a constant infusion rate. The intravenous infusion should be followed by a 10 mL normal saline flush of the intravenous line. Reclast solution for infusion must not be allowed to come in contact with any calcium or other divalent cation-containing solutions, and should be administered as a single intravenous solution through a separate vented infusion line.
If refrigerated, allow the refrigerated solution to reach room temperature before administration. After opening, the solution is stable for 24 hours at 2°C to 8°C (36°F to 46°F) [see How Supplied/Storage and Handling (16)].
Kidney dosing: Renal impairment (US label) US FDA label
8.6 Renal Impairment Reclast is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment. There are no safety or efficacy data to support the adjustment of the Reclast dose based on baseline renal function. Therefore, no dosage adjustment is required in patients with a creatinine clearance of greater than or equal to 35 mL/min [see Warnings and Precautions (5.3), Clinical Pharmacology (12.3)].
Risk of acute renal failure may increase with underlying renal disease and dehydration secondary to fever, sepsis, gastrointestinal losses, diuretic therapy, advanced age, etc. [see Adverse Reactions (6.2)].
Renal Impairment: The pharmacokinetic studies conducted in 64 cancer patients represented typical clinical populations with normal to moderately-impaired renal function. Compared to patients with creatinine clearance greater than 80 mL/min (N = 37), patients with creatinine clearance = 50-80 mL/min (N = 15) showed an average increase in plasma AUC of 15%, whereas patients with creatinine clearance = 30-50 mL/min (N = 11) showed an average increase in plasma AUC of 43%.
No dosage adjustment is required in patients with a creatinine clearance of greater than or equal to 35 mL/min. Reclast is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see Contraindications (4), Warnings and Precautions (5.3), Use in Specific Populations (8.6)].
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS 5 mg in a 100 mL ready to infuse solution. 5 mg in a 100 mL ready-to-infuse solution (3)
- • Products Containing Same Active Ingredient: Patients receiving Zometa should not receive Reclast (5.1)
- • Hypocalcemia may worsen during treatment. Patients must be adequately supplemented with calcium and vitamin D (5.2)
- • Renal Impairment: A single dose should not exceed 5 mg and the duration of infusion should be no less than 15 minutes. Renal toxicity may be greater in patients with underlying renal impairment or with other risk factors, including advanced age or dehydration. Monitor creatinine clearance before each dose (2.7, 5.3)
- • Osteonecrosis of the Jaw (ONJ) has been reported. All patients should have a routine oral exam by the prescriber prior to treatment (5.4)
- • Atypical Fractures Including Femoral Fractures have been reported. Patients with thigh or groin pain should be evaluated to rule out a femoral fracture. Risk/benefit of continuing bisphosphonate therapy should be re-evaluated in these patients and interruption of bisphosphonate therapy should be considered (5.5)
- • Severe Bone, Joint, and Muscle Pain may occur. Withhold future doses of Reclast if severe symptoms occur (5.6)
5.1 Drug Products With Same Active Ingredient
5.1 Drug Products With Same Active Ingredient Reclast contains the same active ingredient found in Zometa, used for oncology indications, and a patient being treated with Zometa should not be treated with Reclast.
5.2 Hypocalcemia and Mineral Metabolism
5.2 Hypocalcemia and Mineral Metabolism Preexisting hypocalcemia and disturbances of mineral metabolism (e.g., hypoparathyroidism, thyroid surgery, parathyroid surgery; malabsorption syndromes, excision of small intestine) must be effectively treated before initiating therapy with Reclast. Clinical monitoring of calcium and mineral levels (phosphorus and magnesium) is highly recommended for these patients [see Contraindications (4)].
Hypocalcemia following Reclast administration is a significant risk in Paget’s disease. All patients should be instructed about the symptoms of hypocalcemia and the importance of calcium and vitamin D supplementation in maintaining serum calcium levels [see Dosage and Administration (2.8), Adverse Reactions (6.1), Patient Counseling Information (17)].
All osteoporosis patients should be instructed on the importance of calcium and vitamin D supplementation in maintaining serum calcium levels [see Dosage and Administration (2.8), Adverse Reactions (6.1), Patient Counseling Information (17)].
5.3 Renal Impairment
5.3 Renal Impairment A single dose of Reclast should not exceed 5 mg and the duration of infusion should be no less than 15 minutes [see Dosage and Administration (2)]. Reclast is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment [see Contraindications (4)].
If history or physical signs suggest dehydration, Reclast therapy should be withheld until normovolemic status has been achieved [see Adverse Reactions (6.2)]. Reclast should be used with caution in patients with chronic renal impairment. Acute renal impairment, including renal failure, has been observed following the administration of zoledronic acid, especially in patients with preexisting renal compromise, advanced age, concomitant nephrotoxic medications, concomitant diuretic therapy, or severe dehydration occurring before or after Reclast administration.
Acute renal failure (ARF) has been observed in patients after a single administration. Rare reports of hospitalization and/or dialysis or fatal outcome occurred in patients with underlying moderate to severe renal impairment or with any of the risk factors described in this section [see Adverse Reactions (6.2)]. Renal impairment may lead to increased exposure of concomitant medications and/or their metabolites that are primarily renally excreted [see Drug Interactions (7.4)].
Creatinine clearance should be calculated based on actual body weight using Cockcroft-Gault formula before each Reclast dose. Transient increase in serum creatinine may be greater in patients with impaired renal function; interim monitoring of creatinine clearance should be performed in at-risk patients. Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure.
These patients should have their fluid status assessed and be appropriately hydrated prior to administration of Reclast. Reclast should be used with caution with other nephrotoxic drugs [see Drug Interactions (7.3)]. Consider monitoring creatinine clearance in patients at-risk for ARF who are taking concomitant medications that are primarily excreted by the kidney [see Drug Interactions (7.4)].
5.4 Osteonecrosis of the Jaw
5.4 Osteonecrosis of the Jaw Osteonecrosis of the jaw (ONJ) has been reported in patients treated with bisphosphonates, including zoledronic acid. Most cases have been in cancer patients treated with intravenous bisphosphonates undergoing dental procedures. Some cases have occurred in patients with postmenopausal osteoporosis treated with either oral or intravenous bisphosphonates.
A routine oral examination should be performed by the prescriber prior to initiation of bisphosphonate treatment. A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy).
The risk of ONJ may increase with duration of exposure to bisphosphonates. Concomitant administration of drugs associated with ONJ may increase the risk of developing ONJ. While on treatment, patients with concomitant risk factors should avoid invasive dental procedures if possible. For patients who develop ONJ while on bisphosphonate therapy, dental surgery may exacerbate the condition.
For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of ONJ. The clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment [see Adverse Reactions (6.1)].
5.5 Atypical Fractures Including Femoral
5.5 Atypical Fractures Including Femoral Fractures Atypical, low-energy, or low trauma fractures of the femoral shaft have been reported during treatment with bisphosphonates, including zolendronic acid, in patients with osteoporosis. Atypical femur and other fractures most commonly occur with minimal or no trauma to the affected area.
These fractures occurred anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or short oblique in orientation without evidence of comminution. Atypical fractures of other bones have also been reported. They may be bilateral. These fractures can also occur in osteoporotic patients who have not been treated with bisphosphonates.
Concomitant treatment with glucocorticoids may also induce these fractures. Prodromal pain in the affected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs. Any patient with a history of bisphosphonate exposure who presents with thigh or groin pain should be suspected of having an atypical fracture and should be evaluated to rule out an incomplete femur fracture.
Bony pain in other locations should also be considered for evaluation of atypical fracture. Patients presenting with an atypical femur fracture should also be assessed for symptoms and signs of fracture in the contralateral limb. Risk/benefit of continuing bisphosphonate therapy should be re-evaluated in these patients and interruption of bisphosphonate therapy should be considered.
5.6 Musculoskeletal Pain
5.6 Musculoskeletal Pain In post-marketing experience, severe and occasionally incapacitating bone, joint, and/or muscle pain have been infrequently reported in patients taking bisphosphonates, including Reclast. The time to onset of symptoms varied from one day to several months after starting the drug. Consider withholding future Reclast treatment if severe symptoms develop.
Most patients had relief of symptoms after stopping. A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate [see Adverse Reactions (6.2)].
5.7 Patients With Asthma
5.7 Patients With Asthma While not observed in clinical trials with Reclast, there have been reports of bronchoconstriction in aspirin-sensitive patients receiving bisphosphonates. Use Reclast with caution in aspirin-sensitive patients.
The following clinically significant adverse drug reactions are described elsewhere in the labeling:
- Drugs with Same Active Ingredient [see Warnings and Precautions (5.1)]
- Hypocalcemia and Mineral Metabolism [see Warnings and Precautions (5.2)]
- Renal Impairment [see Warnings and Precautions (5.3)]
- Osteonecrosis of the Jaw [see Warnings and Precautions (5.4)]
- Atypical Fractures Including Femoral Fractures [see Warnings and Precautions (5.5)]
- Musculoskeletal Pain [see Warnings and Precautions (5.6)]
- Patients with Asthma [see Warnings and Precautions (5.7)] The most common adverse reactions (greater than 10%) were pyrexia, myalgia, headache, arthralgia, pain in extremity (6.1). Other important adverse reactions were flu-like illness, nausea, vomiting, diarrhea (6.2), and eye inflammation (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Treatment of Osteoporosis in Postmenopausal Women The safety of Reclast in the treatment of postmenopausal osteoporosis was assessed in Study 1, a large, randomized, double-blind, placebo-controlled, multinational study of 7736 postmenopausal women aged 65 to 89 years with osteoporosis, diagnosed by BMD or the presence of a prevalent vertebral fracture.
The duration of the trial was three years with 3862 patients exposed to Reclast and 3852 patients exposed to placebo administered once annually as a single 5 mg dose in 100 mL solution infused over at least 15 minutes, for a total of three doses. All women received 1000 to 1500 mg of elemental calcium plus 400 to 1200 international units of vitamin D supplementation per day.
The incidence of all-cause mortality was similar between groups: 3.4% in the Reclast group and 2.9% in the placebo group. The incidence of serious adverse events was 29.2% in the Reclast group and 30.1% in the placebo group. The percentage of patients who withdrew from the study due to adverse events was 5.4% and 4.8% for the Reclast and placebo groups, respectively.
The safety of Reclast in the treatment of osteoporosis patients with a recent (within 90 days) low-trauma hip fracture was assessed in Study 2, a randomized, double-blind, placebo-controlled, multinational endpoint-driven study of 2127 men and women aged 50 to 95 years; 1065 patients were randomized to Reclast and 1062 patients were randomized to placebo. Reclast was administered once annually as a single 5 mg dose in 100 mL solution infused over at least 15 minutes.
The study continued until at least 211 patients had a confirmed clinical fracture in the study population who were followed for an average of approximately 2 years on study drug. Vitamin D levels were not routinely measured but a loading dose of vitamin D (50,000 to 125,000 international units orally or IM) was given to patients and they were started on 1000 to 1500 mg of elemental calcium plus 800 to 1200 international units of vitamin D supplementation per day for at least 14 days prior to the study drug infusions.
The incidence of all-cause mortality was 9.6% in the Reclast group and 13.3% in the placebo group. The incidence of serious adverse events was 38.3% in the Reclast group and 41.3% in the placebo group. The percentage of patients who withdrew from the study due to adverse events was 5.3% and 4.7% for the Reclast and placebo groups, respectively.
Adverse reactions reported in at least 2% of patients with osteoporosis and more frequently in the Reclast-treated patients than placebo-treated patients in either osteoporosis trial are shown below in Table 1. Table 1. Adverse Reactions Occurring in Greater Than or Equal to 2.0% of Patients with Osteoporosis and More Frequently Than in Placebo-Treated Patients Abbreviation: IV, intravenous or intravenously.
Study 1 Study 2 System Organ Class 5 mg IV Reclast once per year % (N = 3862) Placebo once per year % (N = 3852) 5 mg IV Reclast once per year % (N = 1054) Placebo once per year % (N = 1057) Blood and the Lymphatic System Disorders Anemia 4.4 3.6 5.3 5.2 Metabolism and Nutrition Disorders Dehydration 0.6 0.6 2.5 2.3 Anorexia 2.0 1.1 1.0 1.0 Nervous System Disorders Headache 12.4 8.1 3.9 2.5 Dizziness 7.6 6.7 2.0 4.0 Ear and Labyrinth Disorders Vertigo 4.3 4.0 1.3 1.7 Cardiac Disorders Atrial fibrillation 2.4 1.9 2.8 2.6 Vascular Disorders Hypertension 12.7 12.4 6.8 5.4 Gastrointestinal Disorders Nausea 8.5 5.2 4.5 4.5 Diarrhea 6.0 5.6 5.2 4.7 Vomiting 4.6 3.2 3.4 3.4 Abdominal pain upper 4.6 3.1 0.9 1.5 Dyspepsia 4.3 4.0 1.7 1.6 Musculoskeletal, Connective Tissue and Bone Disorders Arthralgia 23.8 20.4 17.9 18.3 Myalgia 11.7 3.7 4.9 2.7 Pain in extremity 11.3 9.9 5.9 4.8 Shoulder pain 6.9 5.6 0.0 0.0 Bone pain 5.8 2.3 3.2 1.0 Neck pain 4.4 3.8 1.4 1.1 Muscle spasms 3.7 3.4 1.5 1.7 Osteoarthritis 9.1 9.7 5.7 4.5 Musculoskeletal pain 0.4 0.3 3.1 1.2 General Disorders and Administrative-Site Conditions Pyrexia 17.9 4.6 8.7 3.1 Influenza-like illness 8.8 2.7 0.8 0.4 Fatigue 5.4 3.5 2.1 1.2 Chills 5.4 1.0 1.5 0.5 Asthenia 5.3 2.9 3.2 3.0 Peripheral edema 4.6 4.2 5.5 5.3 Pain 3.3 1.3 1.5 0.5 Malaise 2.0 1.0 1.1 0.5 Hyperthermia 0.3 < 0.1 2.3 0.3 Chest Pain 1.3 1.1 2.4 1.8 Investigations Creatinine renal clearance decreased 2.0 2.4 2.1 1.7 Renal Impairment Treatment with intravenous bisphosphonates, including zoledronic acid, has been associated with renal impairment manifested as deterioration in renal function (i.e., increased serum creatinine) and in rare cases, acute renal failure. In the clinical trial for postmenopausal osteoporosis, patients with baseline creatinine clearance less than 30 mL/min (based on actual body weight), urine dipstick greater than or equal to 2+ protein or increase in serum creatinine of greater than 0.5 mg/dL during the screening visits were excluded.
The change in creatinine clearance (measured annually prior to dosing) and the incidence of renal failure and impairment was comparable for both the Reclast and placebo treatment groups over 3 years, including patients with creatinine clearance between 30-60 mL/min at baseline. Overall, there was a transient increase in serum creatinine observed within 10 days of dosing in 1.8% of Reclast-treated patients versus 0.8% of placebo-treated patients which resolved without specific therapy [see Warnings and Precautions (5.3)].
Acute Phase Reaction The signs and symptoms of acute phase reaction occurred in Study 1 following Reclast infusion, including fever (18%), myalgia (9%), flu-like symptoms (8%), headache (7%), and arthralgia (7%). The majority of these symptoms occurred within the first 3 days following the dose of Reclast and usually resolved within 3 days of onset but resolution could take up to 7-14 days.
In Study 2, patients without a contraindication to acetaminophen were provided with a standard oral dose at the time of the IV infusion and instructed to use additional acetaminophen at home for the next 72 hours as needed. Reclast was associated with fewer signs and symptoms of a transient acute phase reaction in this trial: fever (7%) and arthralgia (3%).
The incidence of these symptoms decreased with subsequent doses of Reclast. Laboratory Findings In Study 1, in women with postmenopausal osteoporosis, approximately 0.2% of patients had notable declines of serum calcium levels (less than 7.5 mg/dL) following Reclast administration. No symptomatic cases of hypocalcemia were observed.
In Study 2, following pre-treatment with vitamin D, no patients had treatment emergent serum calcium levels below 7.5 mg/dL. Injection-Site Reactions In the osteoporosis trials, local reactions at the infusion site, such as itching, redness and/or pain have been reported in 0% to 0.7% of patients following the administration of Reclast and 0% to 0.5% of patients following administration of placebo.
Osteonecrosis of the Jaw In the postmenopausal osteoporosis trial, Study 1, in 7736 patients, after initiation of therapy, symptoms consistent with ONJ occurred in one patient treated with placebo and one patient treated with Reclast. Both cases resolved after appropriate treatment [see Warnings and Precautions (5.4)]. No reports of ONJ were reported in either treatment group in Study 2.
Atrial Fibrillation In the postmenopausal osteoporosis trial, Study 1, adjudicated serious adverse events of atrial fibrillation in the zoledronic acid treatment group occurred in 1.3% of patients (50 out of 3862) compared to 0.4% (17 out of 3852) in the placebo group. The overall incidence of all atrial fibrillation adverse events in the zoledronic acid treatment group was reported in 2.5% of patients (96 out of 3862) in the Reclast group vs. 1.9% of patients (75 out of 3852) in the placebo group.
Over 90% of these events in both treatment groups occurred more than a month after the infusion. In an ECG sub-study, ECG measurements were performed on a subset of 559 patients before and 9 to 11 days after treatment. There was no difference in the incidence of atrial fibrillation between treatment groups suggesting these events were not related to the acute infusions.
In Study 2, adjudicated serious adverse events of atrial fibrillation in the zoledronic acid treatment group occurred in 1.0% of patients (11 out of 1054) compared to 1.2% (13 out of 1057) in the placebo group demonstrating no difference between treatment groups. Ocular Adverse Events Cases of iritis/uveitis/episcleritis/conjunctivitis have been reported in patients treated with bisphosphonates, including zoledronic acid.
In the osteoporosis trials, 1 (less than 0.1%) to 9 (0.2%) patients treated with Reclast and 0 (0%) to 1 (less than 0.1%) patient treated with placebo developed iritis/uveitis/episcleritis. Prevention of Osteoporosis in Postmenopausal Women The safety of Reclast in postmenopausal women with osteopenia (low bone mass) was assessed in a 2-year randomized, multi-center, double-blind, placebo-controlled study of 581 postmenopausal women aged greater than or equal to 45 years.
Patients were randomized to one of three treatment groups: (1) Reclast given at randomization and Month 12 (n=198); (2) Reclast given at randomization and placebo at Month 12 (n=181); and (3) placebo given at randomization and Month 12 (n=202). Reclast was administered as a single 5 mg dose in 100 mL solution infused over at least 15 minutes.
All women received 500 to 1200 mg elemental calcium plus 400 to 800 international units vitamin D supplementation per day. The incidence of serious adverse events was similar for subjects given (1) Reclast at randomization and at Month 12 (10.6%), (2) Reclast at randomization and placebo given at Month 12 (9.4%), and (3) placebo at randomization and at Month 12 (11.4%).
The percentages of patients who withdrew from the study due to adverse events were 7.1%, 7.2%, and 3.0% in the two Reclast groups and placebo group, respectively. Adverse reactions reported in at least 2% of patients with osteopenia and more frequently in the Reclast-treated patients than placebo-treated patients are shown in Table 2.
Table 2. Adverse Reactions Occurring in Greater Than or Equal to 2% of Patients with Osteopenia and More Frequently Than in Placebo-Treated Patients Abbreviation: IV, intravenous or intravenously. System Organ Class 5 mg IV Reclast once per year % (n = 198) 5 mg IV Reclast once % (n = 181) Placebo once per year % (n = 202) Metabolism and nutrition Disorders Anorexia 2.0 0.6 0.0 Nervous system Disorders Headache 14.6 20.4 11.4 Dizziness 7.6 6.1 3.5 Hypoesthesia 5.6 2.2 2.0 Ear and Labyrinth Disorders Vertigo 2.0 1.7 1.0 Vascular Disorders Hypertension 5.1 8.3
6.9 Gastrointestinal Disorders Nausea 17
6.9 Gastrointestinal Disorders Nausea 17.7 11.6 7.9 Diarrhea 8.1 6.6 7.9 Vomiting 7.6 5.0 4.5 Dyspepsia 7.1 6.6 5.0 Abdominal pain Combined abdominal pain, abdominal pain upper, and abdominal pain lower as one Adverse Drug Reaction (ADR). 8.6 6.6 7.9 Constipation 6.6 7.2
6.9 Abdominal
6.9 Abdominal discomfort 2.0 1.1 0.5 Abdominal distension 2.0 0.6 0.0 Skin and Subcutaneous Tissue Disorders Rash 3.0 2.2 2.5 Musculoskeletal and Connective Tissue Disorders Arthralgia 27.3 18.8 19.3 Myalgia 19.2 22.7
6.9 Back
6.9 Back pain 18.2 16.6 11.9 Pain in extremity 11.1 16.0 9.9 Muscle spasms 5.6 2.8 5.0 Musculoskeletal pain Combined musculoskeletal pain and musculoskeletal chest pain as one ADR. 8.1 7.2 7.9 Bone pain 5.1 3.3 1.0 Neck pain 5.1 6.6 5.0 Arthritis 4.0 2.2 1.5 Joint stiffness 3.5 1.1 2.0 Joint swelling 3.0 0.6 0.0 Flank pain 2.0 0.6 0.0 Pain in jaw 2.0 3.9 2.5 General Disorders and Administration-Site Conditions Pain 24.2 14.9 3.5 Pyrexia 21.7 21.0 4.5 Chills 18.2 18.2 3.0 Fatigue 14.6 9.9 4.0 Asthenia 6.1 2.8 1.0 Peripheral edema 5.6 3.9 3.5 Non-cardiac chest pain 3.5 7.7 3.0 Influenza-like illness 1.5 3.3 2.0 Malaise 1.0 2.2 0.5 Ocular Adverse Events Cases of iritis/uveitis/episcleritis/conjunctivitis have been reported in patients treated with bisphosphonates, including zoledronic acid. In the osteoporosis prevention trial, 4 (1.1%) patients treated with Reclast and 0 (0%) patients treated with placebo developed iritis/uveitis.
Acute Phase Reaction In patients given Reclast at randomization and placebo at Month 12, Reclast was associated with signs and symptoms of an acute phase reaction: myalgia (20.4%), fever (19.3%), chills (18.2%), pain (13.8%), headache (13.3%), fatigue (8.3%), arthralgia (6.1%), pain in extremity (3.9%), influenza-like illness (3.3%), and back pain (1.7%), which occurred within the first 3 days following the dose of Reclast. The majority of these symptoms were mild to moderate and resolved within 3 days of the event onset but resolution could take up to 7-14 days.
Osteoporosis in Men The safety of Reclast in men with osteoporosis or osteoporosis secondary to hypogonadism was assessed in a two year randomized, multicenter, double-blind, active controlled group study of 302 men aged 25 to 86 years. One hundred fifty three (153) patients were exposed to Reclast administered once annually with a 5 mg dose in 100 mL infused over 15 minutes for up to a total of two doses, and 148 patients were exposed to a commercially-available oral weekly bisphosphonate (active control) for up to two years.
All participants received 1000 mg of elemental calcium plus 800 to 1000 international units of vitamin D supplementation per day. The incidence of all-cause mortality (one in each group) and serious adverse events were similar between the Reclast and active control treatment groups. The percentage of patients experiencing at least one adverse event was comparable between the Reclast and active control groups, with the exception of a higher incidence of post-dose symptoms in the Reclast group that occurred within 3 days after infusion.
The overall safety and tolerability of Reclast was similar to the active control. Adverse reactions reported in at least 2% of men with osteoporosis and more frequently in the Reclast-treated patients than the active control-treated patients and either (1) not reported in the postmenopausal osteoporosis treatment trial or (2) reported more frequently in the trial of osteoporosis in men are presented in Table 3.
Therefore, Table 3 should be viewed in conjunction with Table 1. Table 3: Adverse Reactions Occurring in Greater Than or Equal to 2% of Men with Osteoporosis and More Frequently in the Reclast-Treated Patients Than the Active Control-Treated Patients and Either (1) Not Reported in the Postmenopausal Osteoporosis Treatment Trial or (2) Reported More Frequently in This Trial Abbreviation: IV, intravenous or intravenously.
System Organ Class 5 mg IV Reclast once per year % (N = 153) Active Control once weekly % (N = 148) Nervous System Disorders Headache 15.0
6.1 Lethargy 3
6.1 Lethargy 3.3 1.4 Eye Disorders Eye pain 2.0 0.0 Cardiac Disorders Atrial fibrillation 3.3 2.0 Palpitations 2.6 0.0 Respiratory, Thoracic and Mediastinal Disorders Dyspnea 6.5 4.7 Abdominal pain Combined abdominal pain, abdominal pain upper, and abdominal pain lower as one Adverse Drug Reaction (ADR). 7.9 4.1 Skin and Subcutaneous Tissue Disorders Hyperhidrosis 2.6 2.0 Musculoskeletal, Connective Tissue and Bone Disorders Myalgia 19.6
6.8 Musculoskeletal
6.8 Musculoskeletal pain Combined musculoskeletal pain and musculoskeletal chest pain as one ADR. 12.4 10.8 Musculoskeletal stiffness 4.6 0.0 Renal and Urinary Disorders Blood creatinine increased 2.0 0.7 General Disorders and Administrative-Site Conditions Fatigue 17.6
6.1 Pain 11
6.1 Pain 11.8 4.1 Chills 9.8 2.7 Influenza-like illness 9.2 2.0 Malaise 7.2 0.7 Acute phase reaction 3.9 0.0 Investigations C-reactive protein increased 4.6 1.4 Renal Impairment Creatinine clearance was measured annually prior to dosing and changes in long-term renal function over 24 months were comparable in the Reclast and active control groups [see Warnings and Precautions (5.3)]. Acute Phase Reaction Reclast was associated with signs and symptoms of an acute phase reaction: myalgia (17.1%), fever (15.7%), fatigue (12.4%), arthralgia (11.1%), pain (10.5%), chills (9.8%), headache (9.8%), influenza-like illness (8.5%), malaise (5.2%), and back pain (3.3%), which occurred within the first 3 days following the dose of Reclast.
The majority of these symptoms were mild to moderate and resolved within 3 days of the event onset but resolution could take up to 7-14 days. The incidence of these symptoms decreased with subsequent doses of Reclast. Atrial Fibrillation The incidence of all atrial fibrillation adverse events in the Reclast treatment group was 3.3% (5 out of 153) compared to 2.0% (3 out of 148) in the active control group.
However, there were no patients with adjudicated serious adverse events of atrial fibrillation in the Reclast treatment group. Laboratory Findings There were no patients who had treatment emergent serum calcium levels below 7.5 mg/dL. Injection-Site Reactions There were 4 patients (2.6%) on Reclast vs. 2 patients (1.4%) on active control with local-site reactions.
Osteonecrosis of the Jaw In this trial, there were no cases of ONJ [see Warnings and Precautions (5.4)]. Glucocorticoid-Induced Osteoporosis The safety of Reclast in men and women in the treatment and prevention of glucocorticoid-induced osteoporosis was assessed in a randomized, multicenter, double-blind, active controlled, stratified study of 833 men, and women aged 18 to 85 years treated with greater than or equal to 7.5 mg/day oral prednisone (or equivalent).
Patients were stratified according to the duration of their pre-study corticosteroid therapy: less than or equal to 3 months prior to randomization (prevention subpopulation), and greater than 3 months prior to randomization (treatment subpopulation). The duration of the trial was one year with 416 patients exposed to Reclast administered once as a single 5 mg dose in 100 mL infused over 15 minutes, and 417 patients exposed to a commercially-available oral daily bisphosphonate (active control) for one year.
All participants received 1000 mg of elemental calcium plus 400 to 1000 international units of vitamin D supplementation per day. The incidence of all-cause mortality was similar between treatment groups: 0.9% in the Reclast group and 0.7% in the active control group. The incidence of serious adverse events was similar between the Reclast treatment and prevention groups, 18.4% and 18.1%, respectively, and the active control treatment and prevention groups, 19.8% and 16.0%, respectively.
The percentage of subjects who withdrew from the study due to adverse events was 2.2% in the Reclast group vs. 1.4% in the active control group. The overall safety and tolerability were similar between Reclast and active control groups with the exception of a higher incidence of post-dose symptoms in the Reclast group that occurred within 3 days after infusion.
The overall safety and tolerability profile of Reclast in glucocorticoid-induced osteoporosis was similar to the adverse events reported in the Reclast postmenopausal osteoporosis clinical trial. Adverse reactions reported in at least 2% of patients that were either not reported in the postmenopausal osteoporosis treatment trial or reported more frequently in the treatment and prevention of glucocorticoid-induced osteoporosis trial included the following: abdominal pain (Reclast 7.5%; active control 5.0%), and musculoskeletal pain (Reclast 3.1%; active control 1.7%).
Other musculoskeletal events included back pain (Reclast 4.3%, active control 6.2%), bone pain (Reclast 3.1%, active control 2.2%), and pain in the extremity (Reclast 3.1%, active control 1.2%). In addition, the following adverse events occurred more frequently than in the postmenopausal osteoporosis trial: nausea (Reclast 9.6%; active control 8.4%), and dyspepsia (Reclast 5.5%; active control 4.3%).
Renal Impairment Renal function measured prior to dosing and at the end of the 12-month study was comparable in the Reclast and active control groups [see Warnings and Precautions (5.3)]. Acute Phase Reaction Reclast was associated with signs and symptoms of a transient acute phase reaction that was similar to that seen in the Reclast postmenopausal osteoporosis clinical trial.
Atrial Fibrillation The incidence of atrial fibrillation adverse events was 0.7% (3 of 416) in the Reclast group compared to no adverse events in the active control group. All subjects had a prior history of atrial fibrillation and no cases were adjudicated as serious adverse events. One patient had atrial flutter in the active control group.
Laboratory Findings There were no patients who had treatment emergent serum calcium levels below 7.5 mg/dL. Injection-Site Reactions There were no local reactions at the infusion site. Osteonecrosis of the Jaw In this trial there were no cases of ONJ [see Warnings and Precautions (5.4)]. Paget’s Disease of Bone In the Paget’s disease trials, two 6-month, double-blind, comparative, multinational studies of 349 men, and women aged greater than 30 years with moderate to severe disease and with confirmed Paget’s disease of bone, 177 patients were exposed to Reclast and 172 patients exposed to risedronate.
Reclast was administered once as a single 5 mg dose in 100 mL solution infused over at least 15 minutes. Risedronate was given as an oral daily dose of 30 mg for 2 months. The incidence of serious adverse events was 5.1% in the Reclast group and 6.4% in the risedronate group. The percentage of patients who withdrew from the study due to adverse events was 1.7% and 1.2% for the Reclast and risedronate groups, respectively.
Adverse reactions occurring in at least 2% of the Paget’s patients receiving Reclast (single 5 mg intravenous infusion) or risedronate (30 mg oral daily dose for 2 months) over a 6-month study period are listed by system organ class in Table 4. Table 4. Adverse Reactions Reported in at Least 2% of Paget’s Patients Receiving Reclast (Single 5 mg Intravenous Infusion) or Risedronate (Oral 30 mg Daily for 2 Months) Over a 6-Month Follow-up Period Abbreviation: IV, intravenous or intravenously.
System Organ Class 5 mg IV Reclast % (N = 177) 30 mg/day x 2 Months risedronate % (N = 172) Infections and Infestations Influenza 7 5 Metabolism and Nutrition Disorders Hypocalcemia 3 1 Anorexia 2 2 Nervous System Disorders Headache 11 10 Dizziness 9 4 Lethargy 5 1 Paresthesia 2 0 Respiratory, Thoracic and Mediastinal Disorders Dyspnea 5 1 Gastrointestinal Disorders Nausea 9 6 Diarrhea 6 6 Constipation 6 5 Dyspepsia 5 4 Abdominal distension 2 1 Abdominal pain 2 2 Vomiting 2 2 Abdominal pain upper 1 2 Skin and Subcutaneous Tissue Disorders Rash 3 2 Musculoskeletal, Connective Tissue and Bone Disorders Arthralgia 9 11 Bone pain 9 5 Myalgia 7 4 Back pain 4 7 Musculoskeletal stiffness 2 1 General Disorders and Administrative-Site Conditions Influenza-like illness 11 6 Pyrexia 9 2 Fatigue 8 4 Rigors 8 1 Pain 5 4 Peripheral edema 3 1 Asthenia 2 1 Laboratory Findings In the Paget’s disease trials, early, transient decreases in serum calcium and phosphate levels were observed. Approximately 21% of patients had serum calcium levels less than 8.4 mg/dL 9-11 days following Reclast administration.
Renal Impairment In clinical trials in Paget’s disease, there were no cases of renal deterioration following a single 5 mg 15-minute infusion [see Warnings and Precautions (5.3)]. Acute Phase Reaction The signs and symptoms of acute phase reaction (influenza-like illness, pyrexia, myalgia, arthralgia, and bone pain) were reported in 25% of patients in the Reclast-treated group compared to 8% in the risedronate-treated group.
Symptoms usually occur within the first 3 days following Reclast administration. The majority of these symptoms resolved within 4 days of onset. Osteonecrosis of the Jaw Osteonecrosis of the jaw has been reported with zoledronic acid [see Warnings and Precautions (5.4)].
6.2 Post-Marketing Experience
6.2 Post-Marketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during post approval use of Reclast or bisphosphonate products: Acute Phase Reactions Fever, headache, flu-like symptoms, nausea, vomiting, diarrhea, arthralgia, and myalgia.
Symptoms may be significant and lead to dehydration. Acute Renal Failure Acute renal failure requiring hospitalization and/or dialysis or with a fatal outcome have been rarely reported. Increased serum creatinine was reported in patients with 1) underlying renal disease, 2) dehydration secondary to fever, sepsis, gastrointestinal losses, or diuretic therapy, or 3) other risk factors, such as advanced age, or concomitant nephrotoxic drugs in the post-infusion period.
Transient rise in serum creatinine can be correctable with intravenous fluids. Allergic Reactions Allergic reactions with intravenous zoledronic acid, including anaphylactic reaction/shock, urticaria, angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis, and bronchoconstriction have been reported. Asthma Exacerbations Asthma exacerbations have been reported.
Hypocalcemia Hypocalcemia has been reported. Hypophosphatemia Hypophosphatemia has been reported. Osteonecrosis of the Jaw Osteonecrosis of the jaw has been reported. Osteonecrosis of Other Bones Cases of osteonecrosis of other bones (including femur, hip, knee, ankle, wrist and humerus) have been reported; causality has not been determined in the population treated with Reclast.
Musculoskeletal Low-energy femoral shaft and subtrochanteric fractures, and atypical fractures of other bones [see Warnings and Precautions (5.5)] Ocular Adverse Events Cases of the following events have been reported: conjunctivitis, iritis, iridocyclitis, uveitis, episcleritis, scleritis, and orbital inflammation/edema. Other Hypotension in patients with underlying risk factors has been reported.
Pediatric use (US label) US FDA label
8.4 Pediatric Use Reclast is not indicated for use in children. The safety and effectiveness of zoledronic acid was studied in a one-year active controlled trial of 152 pediatric subjects (74 receiving zoledronic acid). The enrolled population was subjects with severe osteogenesis imperfecta, aged 1 to 17 years, 55% male, 84% Caucasian, with a mean lumbar spine BMD of 0.431 gm/cm 2, which is 2.7 standard deviations below the mean for age-matched controls (BMD Z-score of -2.7).
At one year, increases in BMD were observed in the zoledronic acid treatment group. However, changes in BMD in individual patients with severe osteogenesis imperfecta did not necessarily correlate with the risk for fracture or the incidence or severity of chronic bone pain. The adverse events observed with zoledronic acid use in children did not raise any new safety findings beyond those previously seen in adults treated for Paget’s disease of bone and treatment of osteoporosis, including ONJ and renal impairment.
However, adverse reactions seen more commonly in pediatric patients included pyrexia (61%), arthralgia (26%), hypocalcemia (22%), and headache (22%). These reactions, excluding arthralgia, occurred most frequently within three days after the first infusion and became less common with repeat dosing. No cases of ONJ or renal impairment were observed in this study.
Because of long-term retention in bone, Reclast should only be used in children if the potential benefit outweighs the potential risk. Plasma zoledronic acid concentration data was obtained from 10 patients with severe osteogenesis imperfecta (4 in the age group of 3 to 8 years and 6 in the age group of 9 to 17 years) infused with 0.05 mg/kg dose over 30 minutes.
Mean C max and AUC (0-last) was 167 ng/mL and 220 ng.h/mL, respectively. The plasma concentration time profile of zoledronic acid in pediatric patients represent a multi-exponential decline, as observed in adult cancer patients at an approximately equivalent mg/kg dose.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Pharmacokinetic data in patients with osteoporosis and Paget's disease of bone are not available. Distribution: Single or multiple (every 28 days) 5-minute or 15-minute infusions of 2, 4, 8, or 16 mg zoledronic acid were given to 64 patients with cancer and bone metastases. The post-infusion decline of zoledronic acid concentrations in plasma was consistent with a triphasic process showing a rapid decrease from peak concentrations at end-of-infusion to less than 1% of C max 24 hours post infusion with population half-lives of t 1/2α 0.24 hour and t 1/2β 1.87 hours for the early disposition phases of the drug.
The terminal elimination phase of zoledronic acid was prolonged, with very low concentrations in plasma between Days 2 and 28 post infusion, and a terminal elimination half-life t 1/2γ of 146 hours. The area under the plasma concentration versus time curve (AUC 0-24h) of zoledronic acid was dose proportional from 2 to 16 mg.
The accumulation of zoledronic acid measured over three cycles was low, with mean AUC 0-24h ratios for cycles 2 and 3 versus 1 of 1.13 ± 0.30 and 1.16 ± 0.36, respectively. In vitro and ex vivo studies showed low affinity of zoledronic acid for the cellular components of human blood. In vitro mean zoledronic acid protein binding in human plasma ranged from 28% at 200 ng/mL to 53% at 50 ng/mL.
Metabolism: Zoledronic acid does not inhibit human P450 enzymes in vitro. Zoledronic acid does not undergo biotransformation in vivo. In animal studies, less than 3% of the administered intravenous dose was found in the feces, with the balance either recovered in the urine or taken up by bone, indicating that the drug is eliminated intact via the kidney.
Following an intravenous dose of 20 nCi 14 C-zoledronic acid in a patient with cancer and bone metastases, only a single radioactive species with chromatographic properties identical to those of parent drug was recovered in urine, which suggests that zoledronic acid is not metabolized. Excretion: In 64 patients with cancer and bone metastases on average (± SD) 39 ± 16% of the administered zoledronic acid dose was recovered in the urine within 24 hours, with only trace amounts of drug found in urine post Day 2.
The cumulative percent of drug excreted in the urine over 0-24 hours was independent of dose. The balance of drug not recovered in urine over 0-24 hours, representing drug presumably bound to bone, is slowly released back into the systemic circulation, giving rise to the observed prolonged low plasma concentrations. The 0-24 hour renal clearance of zoledronic acid was 3.7 ± 2.0 L/h.
Zoledronic acid clearance was independent of dose but dependent upon the patient’s creatinine clearance. In a study in patients with cancer and bone metastases, increasing the infusion time of a 4 mg dose of zoledronic acid from 5 minutes (n=5) to 15 minutes (n=7) resulted in a 34% decrease in the zoledronic acid concentration at the end of the infusion ([mean ± SD] 403 ± 118 ng/mL vs. 264 ± 86 ng/mL) and a 10% increase in the total AUC (378 ± 116 ng x h/mL vs. 420 ± 218 ng x h/mL).
The difference between the AUC means was not statistically significant. Specific Populations Pediatrics: Reclast is not indicated for use in children [see Pediatric Use (8.4)]. Geriatrics: The pharmacokinetics of zoledronic acid was not affected by age in patients with cancer and bone metastases whose age ranged from 38 years to 84 years.
Race: The pharmacokinetics of zoledronic acid was not affected by race in patients with cancer and bone metastases. Hepatic Impairment: No clinical studies were conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of zoledronic acid. Renal Impairment: The pharmacokinetic studies conducted in 64 cancer patients represented typical clinical populations with normal to moderately-impaired renal function.
Compared to patients with creatinine clearance greater than 80 mL/min (N = 37), patients with creatinine clearance = 50-80 mL/min (N = 15) showed an average increase in plasma AUC of 15%, whereas patients with creatinine clearance = 30-50 mL/min (N = 11) showed an average increase in plasma AUC of 43%. No dosage adjustment is required in patients with a creatinine clearance of greater than or equal to 35 mL/min.
Reclast is contraindicated in patients with creatinine clearance less than 35 mL/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see Contraindications (4), Warnings and Precautions (5.3), Use in Specific Populations (8.6)].